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Background: Oleanolic acid is a poorly water-soluble natural-derived triterpenoid with 
diverse and important activity, such as hepatoprotective, anti-cancer, anti-inflammatory, 
hypolipidemia and anti-diabetes etc. However, its application is limited for its low water 
solubility and poor oral bioavailability. 
By reducing the particle size to nano range, nanosuspension has been proven to be one 
of the most expeditious and cost-effective methods to improve the solubility and 
bioavailability of poorly water-soluble drugs. Nanosuspension can be produced by top-down 
or bottom-up method and stabilized by polymer and/or surfactants. 
Sucrose esters are a group of nonionic surfactants synthesized by esterification of 
sucrose with fatty acids. They are widely used in food, cosmetic and pharmaceutical area for 
their environmental compatibility: ready biodegradability, low toxicity, low irritation to eyes 
and skin, nontoxic and nonallergenic. Although sucrose esters were found with the ability of 
producing nanoproducts with little energy input, there were not frequently used in preparing 
nanoscaled products.  
 
Purpose: The aim of this study was to develop sucrose ester stabilized oleanolic acid 
nanosuspension to enhance delivery of oleanolic acid by increasing its solubility, bioefficacy 
and bioavailability. Two manufacturing methods, bottom-up and top-down, would be used to 
develop sucrose ester stabilized oleanolic acid nanosuspensions. The product characteristics 
would be evaluated and compared. 
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Methods: O/W emulsion and organic solvent evaporation method, a bottom-up method, 
and wet ball milling method, a top-down method, were both used to prepare sucrose ester 
stabilized oleanolic acid nanosuspension. Designs of experiments were utilized to optimize 
the multiple parameters in wet ball milling method. The particles’ size and polydispersity 
index were measured by nanosizer. Their percent encapsulation efficiency, saturation 
solubility and in vitro dissolution rate were obtained via HPLC. The in vitro bioefficacy was 
analyzed by MTT measurements in A549 human non-small cell lung cancer cell line. The 
cellular uptake of oleanolic acid and in vivo pharmacokinetics profile were determined using 
LC-ESI-MS/MS.  
 
Results: Both methods yielded nano ranged particles (around 100 nm in diameter), 
which were found to be spherical in shape and covered by distinct sucrose ester coating on 
the periphery by TEM observation. Saturation solubility of nanosuspension prepared via 
solvent evaporation method and wet ball milling method were both much larger than free 
drug (3.43 µg/mL). It ranged from 0.66 mg/mL (SEOA91101 NS) to 1.89 mg/mL 
(SEOA4121 NS) in solvent evaporation method, and 2.08 mg/mL (SEOA-EAC NS) to 5.49 
mg/mL (SEOA-HBD NS) in wet ball milling method respectively. However, nanosuspension 
produced by solvent evaporation method was physically and chemically more stable than that 
produced by wet ball milling method. The dissolution rate and cytotoxicity were both 
increased by either of the two methods. Preliminary studies indicated that cellular uptake of 
SEOA nanosuspension by A549 cells was temperature-, concentration- and time-dependent. 
The oral bioavailability also gained a big increase, from 6-7 folds (SEOA4121 NS) to 12 
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folds (SEOA-GBD NS) more than that of oleanolic acid coarse suspension. 
 
Conclusion: Solvent evaporation method and wet ball milling were both successfully in 
preparing SEOA nanosuspension, providing a novel way to enhance saturation solubility, in 
vitro dissolution rate, bioefficacy and in vivo bioavailability of free oleanolic acid and/or 
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CHAPTER 1: INTRODUCTION 
1.1 OLEANOLIC ACID (OA) - A HYDROPHOBIC NATURAL PRODUCT 
OA is a poorly water-soluble natural-derived triterpenoid (Figure 1.1). It has a long 
history of therapeutic use in many Asian countries. In China, it has been marketed as an 
over-the-counter drug to treat liver diseases. However, the low water solubility of OA limits 
its bioavailability, and hence, possibly its efficacy. 
 
1.1.1 NATURAL PRODUCTS 
Discovery and development of new active pharmaceutical ingredients is always a 
multidisciplinary effort and is both time and resource consuming process. Recent studies 
revealed that the average time to discover, develop, and approve a new drug in the United 
States (US) take approximately 14.2 years, with the estimated cost of US $1.3–$1.6 billion 
(1). Adams and Branter also claimed that the cost of drug development is $1 billion and it 
was not an absolute number, however, as there was a substantial variation in drug 
development expenditure depending on the therapeutic category (2). 
 
Natural products or natural compounds have been the main source of many of the 
medicines in use. More than 80 % of drug substances discovered were from natural sources 
or inspired by a natural compound before the era of high-throughput screening (3). Natural 
products still remain to be the major resource to look for new drugs as almost half of the 
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drugs approved since 1994 are based on natural compounds (4). From Alan L. Harvey’s 




Figure 1.1 Molecular structure of oleanolic acid 
 
However, many nature-derived drug candidates have problem with aqueous solubility. 
Poor dissolution rates and consequently, low bioavailabilities of these compounds are the 
consequence of poor aqueous solubility, may result in delays in development or cause the 
compounds to be dropped from clinical use (5-7). To address this problem, chemically 
modified derivatives of nature-derived compounds with improved aqueous solubility have 
been produced (8, 9). Although effective, chemical modification and selection take time as 
well as the need for expensive toxicological studies and not all nature derived compounds are 




1.1.2 OLEANOLIC ACID PHARMACOLOGICAL EFFECT 
1.1.2.1HEPATOPROTECTION EFFECT 
The hepatoprotective effects of OA include protection of acute chemically induced liver 
injury and chronic liver fibrosis as well as cirrhosis (11). OA is still being used either alone 
or in combination with other hepatoprotective ingredients as oral medications. In China, it is 
an over-the-counter drug sold for treating liver disease. OA has shown to be effective at 
alleviating the adverse effects of carbon tetrachloride (CCl4) consumption by enhancing the 
hepatic antioxidant defence system (12). It is believed that at the gene level, OA exerted 
hepatoprotection effect through the dramatic induction of metallothionein (MT) and the 
nuclear factor E2-related factor 2 (Nrf2) by increasing the expression of genes related to cell 
proliferation and suppressing the expression of several cytochrome P450 genes, possibly to 
switch cellular metabolic energy to an acute-phase response mode (13). 
 
1.1.2.2 ANTI-CANCER  
OA has been shown to act at various stages of tumour development, including inhibition 
of tumour genesis, inhibition of tumour promotion, and induction of tumour cell 
differentiation. It can effectively inhibit angiogenesis, invasion of tumour cells and metastasis 
(14). In an experiment examining its ability to inhibit the tumour growth and modify 
haematopoiesis after irradiation, OA showed that it might be effective as an anti-cancer agent 
and possess the ability to decrease undesirable radiation damages on the hematopoietic tissue 
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after radiotherapy (15). OA also has been shown to inhibit mouse skin tumour induced by 
12-O-tetradecanoylphorbol-13-acetate (16).  
1.1.2.3 ANTI-HIV 
Based on the research of Kashiwada et al., OA inhibited HIV-1 replication in acutely 
infected H9 cells with an EC50 value of 1.7 µg/mL, and inhibited H9 cell growth with an IC50 
value of 21.8 µg/mL [therapeutic index (T. I.) 12.8] (17). Mengoni et al. also found that OA 
inhibited the HIV-1 replication in all the cellular systems used (EC50 values: 22.7 µM, 24.6 
µM and 57.4 µM for in vitro infected human peripheral mononuclear cells (PBMC), naturally 




From experiments carried out by Singh et al., OA displayed anti-inflammatory activity 
in carrageenan and dextran-induced oedema in rats via reducing exudate volume and 
inhibiting leukocyte infiltration in carrageenan-induced pleurisy (19). In an in vitro study, 
PC12 cells were used to examine the in vitro antioxidative and anti-inflammatory effects of 





- (20). sPLA2 is a key enzyme in inflammatory reactions. Recent studies 
showed OA inhibited indirect haemolytic activity and mouse paw oedema by inhibiting of in 
vitro and in vivo sPLA2. OA inhibited sPLA2 activities of human synovial fluid (HSF), 
6 
 
human pleural fluid (HPF) and VIPERA RUSSELLI (VRV-PL-V) and NAJA NAJA 
(NN-PL-I) snake venoms in a concentration-dependent manner (21).  
1.1.2.5 OTHER PHARMACOLOGICAL EFFECT 
OA showed anti-pruritic effect on pruritic model in mice induced by a compound 48/80 
(22). OA demonstrated its spasmolytic activity mediated through blockade of calcium influx 
(23). It is also reported to possess other pharmacological effects such as hypolipidemia and 
anti-diabetes (24).  
1.1.3 DOSE AND ADMINISTRATION 
OA is marketed as oral over-the-counter tablets (Shen Zhen Haiwang Pharmaceutical 
Ltd. Co., Shen Zhen, Guangdong, China; reference link: 
http://www.0514zx.com/jiuyizhinan/yaopin/gdyy/200910/623732.html). Each tablet contains 
10 mg of OA together with other excipients. The usual oral dose for adult patients with acute 
hepatitis is 2-4 tablets thrice daily, whereas that of adult patients with chronic hepatitis is 4-8 
tablets thrice daily.  
 
1.1.4 BIOAVAILABILITY OF OLEANOLIC ACID 
Like other natural compounds, although with diverse effect, and its derivatives 
CDDO-Me and CDDO-Imm showed promising antitumor activities and are presently under 
evaluation in phase I clinical studies (25, 26), the application of OA is limited due to its low 
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bioavailability arising from its low aqueous solubility. 
According to the USA FDA Biopharmaceutics Classification System (BCS) Guidance 
(http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm128219.htm), OA should fall in 
the Class IV category because of its low aqueous solubility (4.37 µg/mL) (27) and low 
permeability (Papp = 1.1–1.3×10−6 cm/s in the apical-to-basolateral direction at 10 and 20 
µM) (28). As a result, the oral bioavailability values of OA in rats at doses of 25 and 50 
mg/kg were as low as 0.7 % (28). 
Besides chemical modifications, which is not applicable to all naturally derived 
compounds, a variety of formulation strategies have been developed to improve the solubility 
and, thus, the bioavailability of OA and other natural products. 
 
1.2 FORMULATION STRATEGIES OF INCREASING WATER SOLUBILITY AND 
DISSOLUTION RATE 
Solubility, in particular equilibrium solubility, is a quantitative term that describes the 
concentration of a solute in a saturated solution at a certain temperature. It is defined as the 
concentration of a compound in solution which is in contact with an excess amount of the 
solid compound when the concentration in solution do not change over time (29). Solubility 
can be influenced by a number of physicochemical means such as intrinsic equilibrium 
solubility or pH alteration, particle size reduction, solid dispersions, 
emulsions/microemulsions, complexation (e.g. cyclodextrins), liposomes, co-solvent systems, 
micelles among others. 
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Low equilibrium solubility of hydrophobic compounds can also be the result of poor 
dissolution rate. Hydrophobic compounds are usually poorly water-wettable as well. Upon 
adding to water, the hydrophobic particles often float with minimal wetting, which result in 
their very slow rates of dissolution. According to Nernst-Brunner equation (30):  
dM/ dt =S*D/h*(CS- C) 
where M is the mass of drug dissolved in time t, CS is the saturation solubility of the 
solute, C is the bulk concentration of the solute in the medium at time t, D is the diffusion 
coefficient of the solute in the dissolution medium, S is the specific surface area of the solids, 
and h is the stagnant layer thickness. 
Dissolution process is defined by a time-dependent differential equation (dM/dt). Two 
major steps are normally involved in the dissolution of molecules from the solid surface (31). 
The first step involves the detachment of molecules from the solid surface, which is followed 
by diffusion of the detached molecule across the diffusion layer adjacent to the solid surface. 
In most cases, the first step is easily achievable whereas the second step is usually the 
rate-limiting step that determines the overall dissolution rate. Step two often limits the 
solubility of hydrophobic compounds. 
By changing the solute’s intrinsic equilibrium solubility, modification of drug crystal 
form improves solubility and dissolution rate (32). Using pH-solubility and pH-dissolution 
rate interrelationships, diffusion layer pH was found to influence solubility and dissolution 
rates for haloperidol and its two different salt forms, hydrochloride and mesylate (33).The 
solubility and dissolution rate of a poorly water-soluble drug can also be significantly 
enhanced by the preparation of solid dispersions (34). Likewise, other formulation methods 
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achieved success in enhancing the solubility and dissolution rate of water-insoluble drugs. 
For example, using liposomes (35), emulsions (36), microemulsions (37), micelles (38) and 
inclusion complexes employing cyclodextrins (39-41) had all been reported to be capable of 
improving drug dissolution. However, these formulation methods all have their restricted 
application scope and are not universal in approach, applicable to most poorly water-soluble 
drugs. Therefore, a formulation strategy which can suit most of hydrophobic drugs is much 
preferred. 
The aqueous solubility, dissolution rate and bioavailability of poorly soluble drugs are 
often intrinsically related to drugs’ particle sizes (42, 43). As indicated in Nernst-Brunner 
equation, the dissolution rate of a compound can be increased by reduction of particle size 
which increases the total surface area for dissolution. Therefore, by reducing particle size, 
nanosuspension (NS) can increase surface area that leads to improved the dissolution rate and 
of hydrophobic compounds and this is often accepted as one of the most expeditious and 
effective methods to improve the solubility and bioavailability of poorly water-soluble drugs. 
For the point of simplicity and efficaciousness, NS preparation confers over other 
formulation strategies, NS has revealed its potential to be the universal technique to tackle the 
most of the problems associated with the delivery of poorly water-soluble drugs (44).  
 
1.3 NANOSUSPENSIONS 
In more recent years, more and more NS products have come into market or are under 
clinical trials (Table 1.1). NS refers to a colloidal dispersion of drug nanoparticles that are 
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produced using by a suitable method (precipitation, pearl milling, or high-pressure 
homogenization) and stabilized by adjuvants such as polymers and/or surfactants (27, 45, 46). 
In either method, a high Gibbs free energy (ΔG) is produced with the nanoscaled products. In 
the formula forwarded by B.E. Rabinow (47), ΔG = γs/l •ΔA, where γs/l is the interfacial 
tension and ΔA is the increased surface area. The Gibbs free energy (ΔG) arises because 
water molecules incur less attractive forces with other water molecules when located at the 
free solids’ surfaces (47). Since the Gibbs free energy is higher, the nanosuspensions formed 
are thermodynamically unstable and will tend to minimize their total energy by precipitation 
or agglomeration (48). As indicated by the Rabinow’s formula, Gibbs free energy can be 
lowered down by decreasing the interfacial tension (γs/l ), which can be achieved by adding 
stabilizers (polymers and / or surfactants) to the system. Stabilizers are needed to wet the 
surface of the hydrophobic surfaces of the drug particles first and then form barriers against 
agglomeration or precipitation. These barriers include electrostatic coats produced by charged 
surfactants or steric coats with the non-ionic surfactants or polymers (49). 
 
1.3.1 METHODS OF PREPARATION NANOSUSPENSIONS 
In general, NS preparation methods consist two categories. One category can be 
described as a top-down method, i.e. by breaking of large drug particles into nanosized 
fragments through milling or homogenization. The other category is bottom-up method, by 




Table 1.1 Summary of nanosuspension-based formulations of drugs in market or in 
different clinical trials, modified from reference (47) 
 
Drug  Indication Pharma Company Route Status 
Paclitaxel Anti-cancer American 
Pharmaceutical  
Partners 
Intravenous Phase III  
Rapamune 
(Sirolimus) 
Immuno-suppressant Wyeth Oral Marketed 
Emend 
(aprepitant) 
Anti-emetic Merck Oral Marketed 
Cytokine 
inhibitor 
Crohn’s disease Cytokine  
PharmaSciences 
Oral Phase II 
Diagnostic 
agent 
Imaging agent Photogen Intravenous Phase I/ 
II 
Thymectacin Anticancer agent NewBiotics./Ilex 
Oncology 
Intravenous Phase I/ 
II 
Budesonide Asthma Sheffield 
Pharmaceuticals 
Pulmonary Phase I 
Tricor 
(fenofibrate) 
Lipid Lowering Undisclosed Oral Marketed 
Fenofibrate Lipid Lowering Undisclosed Oral Phase I 
Busulfan Anticancer Supergen Intrathecal Phase I 
Silver Eczema, atopic dermatitis Self-developed Topical Phase I 




adjuvant for herpes 
















NS can be produced by high shear media milling or pearl milling. The milling medium 
is usually made of glass, zirconium oxide or highly cross-linked polystyrene resin. Nanosized 
particles were broken down from micron-sized drug particles by the energy generated from 
the impaction of the milling media with drug at high energy and shear forces supplied during 
milling process (44) .  
Liversidge et al. first introduced and patented the pearl milling technology (51) and it 
was later acquired by Elan Drug Delivery Company. The pearl mill generally consists of a 
stainless steel vessel filled with steel, glass or hard polystyrene balls. The mill operates by 
moving the balls with an impeller while keeping the vessel either static or with movements 
while the balls inside also move. Advantages of pearl milling include suitability for most 
drugs with poor solubility, usable for both aqueous and organic media, easy to scale up, little 
batch-to-batch variation and narrow size distribution of the final nanosized products (44). 
However, the milling methods associated with high energy input and are regarded as 
being highly inefficient (52). Considerable amount of heat is generated which may cause 
degradation of heat sensitive active pharmaceutical ingredients (APIs). Milling has also been 
shown to cause mechanical activation at drug particle surfaces (53). One of the other major 
concerns is the potential erosion of the milling media and the contribution to product 





The two most frequently reported homogenization methods are the microfluidizer 
technology and piston gap high pressure homogenization.  
The microfluidizer technology can generate small particles by a frontal collision of two 
fluid suspensions under high pressures (55). The high speed collisions of sprayed suspension 
lead to particle collisions with high shear forces as well as cavitation forces (56). Surfactants 
are required to stabilize particles produced at the desired particle size. The disadvantages of 
this method are the relatively large size distribution of particles produced and a high number 
of cycles needed for a sufficient particle size reduction to occur (57).  
Another technology used is the piston gap high pressure homogenization method. This 
patented technology is also referred as the Dissocubes technology developed and patented by 
Muller et al. (58) and technology owned by SkyePharma PLC. In this homogenization 
method, the NS particles are produced in water at room temperature. A drug powder is first 
dispersed in an aqueous surfactant solution and subsequently forced by a piston through the 
tiny homogenization gap with pressures ranging up to 4000 bars (57). 
Homogenization methods have the similar advantages like milling and they include 
flexibility in handling drug in quantities ranging from 1 to 400 mg/mL (59) , ease of scale-up, 
little batch-to-batch variation (60), suitable for drugs with poor solubility in both aqueous and 
organic media, and narrow size distribution of the nanoparticulate drug among others (44).  
The main concerns of homogenization for preparing NS are the use of water which may 
contribute to the hydrolysis effect on water-sensitive drugs (57) and the prerequisite of 
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suspension formation using high-speed mixers before processing by homogenization (44). 
 
1.3.1.3 BOTTOM-UP METHOD 
As reported by B. Van Eerdenbrugh et al. (49), among all the products that were 
approved by the United States Food and Drug Administration (FDA) from the year 2000 
onwards, of all five registered products are based on top-down approaches, four relied on 
media milling and one by high pressure homogenization (49). Although the bottom-up 
approaches hold tremendous potential with respect to improving bioavailability by making 
products of smaller particle sizes and amorphous drug particles, no commercial application of 
these systems has yet been realized (61). 
By the bottom-up approach, the drug is first dissolved in an organic solvent and is then 
precipitated on addition of an anti-solvent in the presence of a stabilizer. Various adaptations 
of this approach include: (i) solvent–anti-solvent method; (ii) supercritical fluid processes; (iii) 
spray drying; and (iv) emulsion–solvent evaporation (47). The method of manufacture can 
significantly impact the formation and stability of NS and hence their overall performance 
(62).  
The main advantages include preparation methods that are relatively simple to carry out 
and do not require expensive equipment, and relatively easy to scale up. The main 
disadvantages of these approaches are related to the use of organic solvents in preparation 
giving rise to concerns association to toxicity of organic solvents as well as difficulties of 
their completely removal (44). Any residual solvent can cause physical and chemical 
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instability of the formulation. This may partially explain why bottom-up method is not as 
frequently used as the top-down method. However, compared with either milling or 
homogenization, bottom-up method does not require as much energy or generate as much 
heat, which can be problematic for unstable or heat sensitive drug. With lower toxicity and / 
or improved technique, it may be promising to prepare NS using the bottom-up method. 
 
1.3.2 NANOSUSPENSIONS CHARACTERIZATION 
A prerequisite for the development of optimized NS is the availability of precise 
characterization procedures. The frequently analysed characteristic parameters for NS are 
described in the following discussions. 
 
1.3.2.1 MEAN PARTICLE SIZE AND PARTICLE SIZE DISTRIBUTION 
The mean particle size and the width of particle size distribution are important attributes 
and are also related to factors such as saturation solubility, dissolution velocity, physical 
stability and even biological performance of NS. It has been reported by Muller and Peters 
(63) that saturation solubility and dissolution velocity showed considerable variations with 
the changing particle size of the drug. 
Dynamic light scattering (DLS) together with photon correlation spectroscopy (PCS) are 
most popular techniques for determining the particle size and size distribution of sub-micron 
particles. DLS is fast and suitable for screening a large quantity of samples with the 
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measuring range from 0.02-2,000 μm (64). PCS is also fast but with a narrower sizing range, 
for particles affected by Brownian motion, from 0.02-3 μm (65). 
1.3.2.2 PARTICLE MORPHOLOGY AND CRYSTALLINE STATE  
It is helpful to understand the morphological or polymorphic changes during nanosizing 
by the particle morphology and crystalline state assessments.  
In order to obtain the actual particle morphology, scanning electron microscopy (SEM) 
(66, 67) or transmission electron microscopy (TEM) (68, 69) can be applied. Magnification 
in a SEM can be ranged from about 10 to 500,000 times. TEM’s observation magnification 
capability can range from 80 to 1 million times. High resolution TEM (HRTEM) can magnify 
even further, to above 50 million times (70).  
It is also vital to investigate the extent of amorphous state during the preparation of NS. 
The changes in the physical state of the drug particles as well as the extent of the amorphous 
fraction can be determined by x-ray diffraction analysis (XRD) (71, 72) and findings can be 
supplemented by measurements using the differential scanning calorimetry (DSC) (67, 73). 
 
1.3.2.3 SATURATION SOLUBILITY 
As discussed, NS has the ability to improve the saturation solubility of hydrophobic 
drugs, the determination of the saturation solubility as well as the increase in saturation 
solubility remains an important investigational parameter. The amount of dissolved drug after 
equilibrium can be quantified usually by either ultraviolet spectroscopy or high pressure 
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liquid chromatography.  
 
1.3.2.4 IN VITRO DISSOLUTION RATE AND IN VIVO PHARMACOKINETICS 
PROFILE 
The determination of dissolution rate is very important for anticipating any possible 
change in the in vivo performance (pharmacokinetics and bioavailability) of the drug product 
(74, 75). 
Since low drug solubility, slow dissolution rate and poor oral bioavailability are 
generally associated with poorly formulated drug products, there is the impetus to improve 
drug formulation to produce drug products that are readily bioavailable. According to 
Ostwald-Freundlich’s equation, log (Cs/Cα)= 2σV/(2.303RTρr), where Cs is the saturation 
solubility, Cα is the solubility of the solid consisting of large particles, σ is the interfacial 
tension of substance, V is the molar volume of the particle material, R is the gas constant, T 
is the absolute temperature, ρ is the density of the solid and r is the radius. By decreasing the 
particle size (r), NS can increase the saturation solubility of OA (Cs).When the nanoscaled 
drug particles are presented with dramatic increase in surface area, the drug’s solubility and 
dissolution rate will be enhanced, and hence, high oral bioavailability can be possible.  
Sigfridsson et al. (74) found that with the reduction of particle size from 12 μm (in 
microsuspensions) to 190 nm (in nanosuspensions), the poorly soluble drug UG558 showed a 
big increase in dissolution rate, absorption rate and bioavailability. The dissolution rate and 
bioavailability of fenofibrate were also shown to be obviously enhanced when formulated as 
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a nanosuspension (76).  
 
1.3.2.5 STABILITY 
As mentioned earlier, a high Gibbs free energy (ΔG) with the nanosuspensions formed 
caused the nanoparticles present to be thermodynamically unstable and tended to minimize 
their total energy by precipitation or agglomeration (48). In their suspended state, the stability 
issues of nanosuspensions can be both physical (e.g. Ostwald ripening ) and chemical (e.g. 
hydrolysis) (49). 
In the classical theory of Ostwald ripening, the ripening rate can be calculated using 





[C( ) V D / RT]
dt 9
       
where ω is the Ostwald ripening rate, rN is the droplet radius, C(∞) is bulk solubility (i.e., the 
molecular concentration that is in thermal equilibrium with a macroscopic bulk phase), γ is 
the interfacial tension, Vm is the molar volume of the dispersed compound, ρ is the density of 
the dispersed phase, D is the diffusion coefficient in the solvent, R is the gas constant and T 
is the temperature (K). 
As the suspension form is not stable, NS is usually stored as a more stable solid form by 
either spray drying or freeze drying. However, some short term stability is also important as 
otherwise it may be very problematical when the NS needed further in vivo or in vitro 
analysis. The most extreme example is hydrosols developed by Gassmann et al. (79). 
Hydrosols developed were colloidal aqueous suspensions containing drug nanoparticles of 
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poorly water-soluble drugs for intravenous administration. They were stabilized by “short 
term stabilizers” agents such as poloxamer and modified gelatines and were stable for only 
about 60 min. To prevent crystallization from occurring, the hydrosols were immediately 
spray dried after production with excipients such as lactose or mannitol and spray dried 
products reconstituted with water just before use. 
The frequently measured short-term stability of products reported ranged from within 7 
days (80), within 14 days (81) to within 30 days (82, 83). 
1.3.3 STABILIZERS IN PREPARATION OF NANOSUSPENSIONS 
Stabilizers used in preparation of NS can be classified into two main categories. 
(a) Electrostatic stabilizer: charged surfactants or polymers, such as isotactic 
poly(4-methyl-1-pentene) (84) and sodium dodecyl sulfonate (85, 86) among others. (b) 
Steric stabilizer: non-ionic surfactants or polymers, such as poloxamers (87), Tween 80 (88, 
89), hydroxylpropylmethyl cellulose and hydroxylpropyl cellulose (90) among others.  
Combinations of more than one stabilizers have at times been preferred for enhanced 
long-term stability (91). Unlike nonionic materials (steric stabilizers), which stabilize NS by 
the steric effect, ionic surfactants and polymers (electrostatic stabilizers) stabilize the NS 
system by electrostatic action or, depending on the molecular weight (chain length), by 
electrosteric action (92). 
Electrostatic stabilizers are effective in aqueous environment, but may become less 
effective in dry state for the ionized state is not maintained (93). They are also sensitive to 
changes in pH and ionic strength. By comparison, steric stabilizers are superior in being less 
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sensitive to electrolyte additions, and are equally efficient in both aqueous and nonaqueous 
environments (92). 
 
1.4 SUCROSE ESTER AS STABILIZERS IN PREPARATION OF 
NANOSUSPENSIONS 
Sucrose ester (SE) is a group of nonionic surfactants synthesized by esterification of 
sucrose, the hydrophilic head, with fatty acids.  
SEs are widely used in food and cosmetic industries. Tual et al. found that with the 
recipe and manufacturing process used to produce dairy foams, sucrose ester was important 
in manufacture and storage dairy foams (94). SEs were also found useful in stimulating 
peptide YY release in the distal intestine and inhibiting protein-induced pancreatic secretion 
in pancreatico-biliary diverted rat model (95). The research investigations carried out by 
Calderilla-Fajardo et al. showed that nanoemulsions formulated with sucrose laureate 
exhibited the highest penetration in the stratum corneum (96). 
Besides the application in food and cosmetic areas, SEs are also important excipients in 
preparing pharmaceutical formulations. SEs have been used to prepare micelles in increasing 
solubility of timobesone acetate (97). The bioavailability of superoxide dismutase was 
improved when encapsulated in reverse micelles prepared by poly (epsilon-caprolactone) and 
SE (98). SEs was also reported to aid in the preparation of microemulsions (99, 100). In 
transdermal drug delivery, Ayala-Bravo et al. found that as penetration enhancers, 
combination of sucrose esters (oleate or laureate) and transcutol was able to temporally alter 
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the stratum corneum barrier properties and promoted penetration of 4-hydroxybenzonitrile 
(101). Cazares-Delgadillo et al. discovered that sucrose laureate enhanced the transdermal 
flux of the ionized form of lidocaine and sucrose oleate promoted permeation of the 
unionized lidocaine (102). 
The broadness of the SE application may be aroused by the fact that SE can be 
synthesized with an extremely wide range of hydrophilic-lipophilic balance (HLB) values, 
i.e., HLB 1–18 (103).  
Biodegradability is a critical factor for ensuring that the concentrations of surfactants or 
polymers remain below deleterious levels. In contrast with petrochemically derived 
surfactants, those derived from food sources such as SEs are attractive because of their 
environmental compatibility: ready biodegradability, low toxicity, low irritation to eyes and 
skin, nontoxic and nonallergenic (104-106). This factor becomes even more apparent in the 
preparation of nanoscaled products where it is usual to require much larger amounts of 
surfactants to stabilize the markedly increased specific surface area. Thus, the availability of 
an environmentally compatible, nontoxic surfactant may be of greater interest to stabilize 
nanonized particles (107). 
Producing nanoscaled products are often associated with the input of high energy and 
shear forces, which is of concern to the chemical and physical stability of final product, and 
amount of drug incorporation (108). SEs were found to have the capability to produce 
nanosized, physiologically acceptable dispersions only by the application of gentle heat with 
moderate shear stress (109).  
As a consequence, SE stabilized nano products may be prepared easily and with less 
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worry of the final product toxicity. However, despite these favourable amenities, SEs had 
been overlooked as stabilizers in preparation of nanoparticles or nanosuspensions till recent 
years (107, 109-113). Some possible reasons for this are the relative lack of SE manufacturers 
and difficulties to secure high purity SE samples. 
1.5 AIMS AND OBJECTIVES 
Although NS is a good method to enhance the saturation solubility and oral 
bioavailability of natural compounds, there is very little research on developing OA NS. 
Chen et al. (27) have reported preparing OA NS stabilized by using polysorbate 80 with 
6-fold increase in saturation solubility but oral bioavailability was not determined. There are 
only a few literature reports on the pharmacokinetics profile of OA in vivo (28, 114, 115). 
Jeong et al. (28) first published the oral bioavailability of OA suspension in rats and it was as 
low as 0.7 %. 
Specific objectives of this present study were designed to address the knowledge gaps 
and they are listed below. 
(a) Investigation of the characteristics (including in vitro dissolution rate) 
of OA NS stabilized by blended SEs using top-down and bottom-up methods 
(b) Since OA was reported to possess anticancer property (14, 116) and 
Gao et al. (117) had reported that OA showed weak cytotoxicity effect against 
A549 cell line, the bioefficacy would also be examined by comparing the 
cytotoxcity of both free and nanosized OA using the A549 cell line. 
(c) With the liquid chromatography-electrospray ionization tandem mass 
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spectrometry assay (LC-ESI-MS/MS) modified from the method used by Song 
and Jeong (28, 115), comparison would be on the in vivo pharmacokinetics profile 
with OA NS and OA coarse suspension. By this method, the intracellular OA 
concentration change can also be monitored to determine its cellular uptake 
manner.  
(d) Comparisons of the top-down and bottom-up approaches will be 
made for evaluating the effects of the preparation methods on nanosuspension 
properties  
This present research is the first reported study for employing SEs as main stabilizer 
when preparing NS of OA. Our hypothesis is by formulating OA into nanosuspension form, 
it can have better saturation solubility, bioefficacy and bioavailability. The results of this 
study would provide a clearer understanding of the significance and impact of the 
formulation method for enhancing saturation solubility, dissolution rate and bioavailability of 
hydrophobic natural compound. This study would also provide the opportunity to enable the 
study of the pharmaceutical application of a water-insoluble natural compound which would 
have otherwise be deemed as unsuitable during the screening stage based on the compound’s 
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CHAPTER 2. DEVELOPMENT AND EVALUATION OF SEOA NS VIA 
EMULSION-SOLVENT EVAPORATION METHOD 
2.1 INTRODUCTION 
SE group contains a series of nonionic surfactants prepared by esterification of sucrose 
with fatty acids of different chain lengths. From the chemical structures as shown in Figure 
2.1, the fatty acid chain of sucrose monolaurate (SEL) possesses 11 alkyl groups while that of 
sucrose monopalmitate (SEP) has 15 alkyl groups. Although both SEs are hydrophilic 
nonionic surfactants, with shorter fatty acid chain, SEL (HLB: 15, xLogP3: 1.5) (118) is more 
hydrophilic than SEP (HLB: 13, xLogP3: 3.2) (119). The term, xLogP3 refers to the 
logarithm of the ratio of concentrations of the unionized solute in octanol and water, 
calculated by XlogP version 3 software (120). NS stabilized with blended SEL and SEP may 
exert synergistic advantage over single SE as the stabilizer surfactant.  
Both SEL and SEP are potentially important surfactants especially in pharmaceutical 
product development research. They have shown to possess good abilities in enhancing the 
solubility and absorption of hydrophobic compounds. Experiments by Lerk (121) showed 
that numerous poorly water-soluble drugs could be solubilised by aqueous sucrose laureate 
solutions at high concentrations, and solubilisation procedures were uncomplicated. In 
determining the ability of surfactants to enhance the absorption of digoxin and celiprolol in 
vitro, the efficacy of surfactants tested were found to be: SEL > polysorbate 20 > 
d-α-tocopheryl polyethylene glycol 1000 succinate (TPGS ) > polysorbate 80 (122). Henry et 
al. (123) found the optimal formulation for the sub-micron emulsion with SEL, SEP and 
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other surfactants, would minimize droplet size during processing and minimize or prevent 
Ostwald ripening.  
 













Sucrose monolaurate (n=10)                     Sucrose monopalmitate (n=14)  
 
Figure 2.1 Chemical structure of sucrose monolaurate (SEL) (a) and sucrose 
monopalmitate (SEP) (b). 
 
SEL was also found to be helpful in fabricating micelles used to solubilise the 
water-insoluble drug, sodium diclofenac (124). 
However, there are very few reported literature studies on nanoscaled products produced 
using either SEL or SEP (96, 123). In comparison with top-down preparation methods, the 
bottom-up method does not require as much energy or heat and hence is more suitable for 
unstable or heat sensitive drugs. However, bottom-up methods are not as frequently used as 
top-down techniques. With lower toxicity and / or improved technique, the bottom-up method 
may become the promising alternative as a technique to prepare NS of poorly water-soluble 
drugs. To meet the increasing needs of biocompatible and low toxicity surfactants for the 
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production of nanosized drugs, this study was proposed with one of the aims to study the 
preparation of SE stabilized OA NS by the emulsion-solvent evaporation method, a 
bottom-up technique. 
Many organic solvents can be used in emulsion-solvent evaporation method including 
acetone (125, 126), chloroform (127, 128) and dichloromethane (129, 130). As the residual 
content of the more toxic organic solvent was a main concern of this method, the lower 
toxicity of acetone was deemed as a more favourable choice of organic solvent for adoption 
as the organic solvent to use.  
 
2.2 MATERIALS 
OA was purchased from Nanjing Qinze Pharmaceutics (Nanjing, China). SEL (batch 
M07A001, 90 % purity) and SEP (batch M07C003, 90 % purity) were donated by Compass 
Foods (Singapore). Methyl thiazolyl tetrazolium (MTT) and F12 Ham Kaighn’s modification 
(F12K) medium were purchased from Sigma Aldrich (St. Louis, MO, USA). A549 human 
non-small cell lung cancer cell line (NSCLC) was purchased from American Type Culture 
Collection (Rockville, MD, USA). Foetal bovine serum (FBS) was purchased from Hyclone 
Laboratories (Logan, UT, USA). 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES) was purchased from Applichem (Darmstadt, Germany). MilliQ water (18.2 MΩ cm 
at 25 °C) was obtained from a Millipore Direct-Q ultra-pure water system (Billerica, MA, 





2.3.1 CRITICAL MICELLAR CONCENTRATION (CMC) DETERMINATION BY 
SURFACE TENSION  
The air/water surface tension measurements of SEL and SEP solutions were determined 
at 20 °C with a tensiometer (Torsion Balance Supplies, Alcester, Warwickshire, UK) equipped 
with a 4 cm circumference platinum ring. Surfactant solutions (from 0.0005 to 0.2 g, %) were 
prepared in double distilled deionized water and equilibrated at room temperature for 24 h 
before use. The surface tension of purified water was measured and found to be 72 mN/m at 
20 °C. The critical micellar concentration (CMC) of SE was determined graphically by the 
plot of surface tension (mN/m) versus the concentration of the detergent. The CMC was read 
off from the intersection of two straight lines, one from the descending part of the curve, and 
the other, through the levelled part of the curve.  
 
2.3.2 OA EQUILIBRIUM SOLUBILITY  
Equilibrium solubility of OA was determined by saturation shake-flask method 
according to the US Pharmacopoeia (USP) XXI (United States Pharmacopeia Convention, 
Inc., Rockville, MD, USA, 1985). The drug was added to distilled water until excess 
undissolved drug appeared which indicated that the solution had reached its saturated 
solubility. Briefly, excess drug was added to conical tubes, each filled with 50 mL distilled 
water, shaken at 100 rpm at 25 °C for 24 h, and observed for the presence of any undissolved 
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drug. If no drug crystals were detected, more drug was introduced and the process repeated 
until undissolved drug crystals appeared and remained undissolved after prolonged agitation. 
The saturated amount of dissolved drug was determined by filtering an aliquot through a 0.22 
μm filter and assaying the supernatant solution using high performance liquid 
chromatography (HPLC) assay as according to the USP prescribed procedure. 
 
2.3.3 PREPARATION OF NS 
NS trials were prepared by emulsion-organic solvent evaporation method, adapted from 
the report by Chen et al. (27). In brief, SEP or / and SEL was / were dissolved in 30 mL water 
in a 50 mL beaker with a magnetic bead at room temperature. The aqueous solution was 
stirred at 800 rpm on a stir plate (Sybron, East Lyme, CT, USA) for about 30 min until all the 
surfactant(s) added was(were) completely dissolved. OA in 15 mL acetone was next added to 
the solution. The resulting o/w emulsion was stirred at 800 rpm overnight in a fume hood 
under a small jet of nitrogen to facilitate diffusion and evaporation of the organic solvent. 
This action resulted in nanoprecipitation and the formation of NS. In the last step of the 
preparation, precipitated materials including OA NS, free OA and SE were suspended in 
same volume of water (30 mL) and stirred for 24 h. Next, the suspension, with excess 
undissolved material, was centrifuged at13, 000 g for 10 min. The centrifuged supernatant 
was filtered through a 0.22 m membrane to give a visually clear NS. The resulting NS was 
used immediately for determination of OA saturation solubility and percent encapsulation 
efficiency (EE %). Detailed compositions of various SEOA NS are shown in Table 2.1.  
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2.3.4 PARTICLE SIZE AND POLYDISPERSITY INDEX (PDI) ANALYSIS 
Dynamic light scattering (DLS) measurements were performed on Zetasizer-3000 
(Malvern Instruments, Malvern, UK) at a wavelength of 532 nm. The scattering angle was 
fixed at 90 and the temperature of the sample was maintained at 25 °C. Particle size and PDI 
determination were carried out using a diluted suspension by adding 4 times of its volume 




Table 2.1 Detailed compositions of nanosuspension (NS) formulations 
 






SELOA 250.00 0.00 25.00 
SEPOA 0.00 250.00 25.00 
SEOA 91101 225.00 25.00 25.00 
SEOA 9121 225.00 25.00 125.00 
SEOA 9151 225.00 25.00 50.00 
SEOA 4121 200.00 50.00 125.00 
SEOA 4151 200.00 50.00 50.00 
SEOA 2151 167.00 83.00 50.00 
 
SELOA (SEL : OA at 10 : 1, w/w), SEPOA NS (SEP : OA at 10 : 1, w/w), SEOA91101 
NS (SEL : SEP at 9 : 1, w/w; SE : OA at 10 : 1, w/w), SEOA9121 NS (SEL : SEP at 9:1, w/w; 
SE : OA at 2 : 1, w/w), SEOA9151 NS (SEL : SEP at 9 : 1, w/w; SE : OA at 5 : 1, w/w), 
SEOA4121 NS (SEL : SEP at 4 : 1, w/w; SE : OA at 2 : 1, w/w), SEOA4151 NS (SEL : SEP 
at 4 : 1, w/w; SE : OA at 5 : 1, w/w), SEOA2151 NS (SEL : SEP at 2 : 1, w/w; SE : OA at 5 : 
1, w/w). 
 
2.3.5 FT-IR MEASUREMENT 
Pure oleanolic acid, blank SEL and SEP mixture (4 : 1, w/w) and lyophilized 
SEOA4121 NS were analysed using a FT-IR Spectrometer (PerkinElmer Spectrum 100 
Series, Norwalk, CT, USA). Samples were mixed with anhydrous potassium bromide (1 : 100) 
and ground in a mortar and then pressed in a hydraulic press (14 tons) to small discs. The 
discs were placed under the infrared beam and the FT-IR spectra were collected in a spectral 






2.3.6 TRANSMISSION ELECTRON MICROSCOPY (TEM)  
Copper grids were coated with 0.25 % Formvar film and carbon in sequence. 
The film faces of the grids were applied with the NS sample and stained with 5 % 
phosphotungstic acid (PTA) subsequently. Excess suspension was carefully blotted off during 
each step. After drying for over 10 min under a bench top lamp, the sample was ready for use. 
TEM photomicrographs were obtained using a transmission electron microscope (JEM 2010, 
JEOL, Tokyo, Japan) operated at 200 kV. 
 
2.3.7 PERCENT ENCAPSULATION EFFICIENCY (EE %) AND SATURATION 
SOLUBILITY  
HPLC analysis was carried out on an Aglient model 1100 (Agilent, Palo Alto, CA, USA) 
using a C18 column (ODS 5 µm, 3.9 mm x 150 mm; Waters, Milford, MA, USA) with 65 % 
acetonitrile and 35 % MilliQ water as the mobile phase. Column temperature was set at 24 °C. 
Flow rate was 1 mL/min and UV detection wavelength was 210 nm. Standard samples were 
dissolved in methanol. Each freshly prepared NS sample was dissolved in at least 5 times its 
volume of methanol to ensure that OA was fully dissolved and fell within the standard 
calibration curve. All samples were filtered through 0.22 µm membranes before 
measurements. The calibration curve over the concentration range of 0.02–0.20 mg/mL was 
constructed by plotting the peak area of the analyte against the concentration spiked for each 
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media. Six independently weighed concentrations (0.02, 0.04, 0.06, 0.08, 0.10, 0.20 mg/mL) 
were used to obtain the calibration plot. The linearity of the assay procedure was determined 
by calculation of a regression line. Each standard, i.e. 20, 40, 60, 80, 100 or 200 μg/mL, was 
tested respectively with five repetitions for each concentration.  
The precision of the HPLC method was assessed by carrying out repeatability and 
intermediate precision tests. The repeatability was evaluated by analysing ten solutions 
containing a known quantity of analyte. The inter-day precision was assessed by testing three 
concentrations (40, 60 and 100 μg/ml) over 3 consecutive days.  
The accuracy of the method was checked for three known concentration levels (40, 60 
and 100 μg/ml) and peak area was recorded. All analyses were repeated six times, and the 
recoveries and respective standard deviations were calculated. 
Concentrations of OA in diluted SEOA NS samples were obtained from the resulting 
peak areas and the regression equation of the calibration curve. Saturation solubility of OA 
was calculated from the amount of OA dissolved in diluted sample multiplied by the dilution 
factor. For calculation of the EE % of OA, the following equation was used, 
EE % = OANS /OAT × 100 % 
where, OANS indicates amount (mg) of OA in NS and OAT indicates total amount (mg) of 




2.3.8 LYOPHILISATION OF SEOA NS AND FREE OA SOLUTION 
SEOA NS and free OA solution were frozen at -80 °C overnight and then freeze dried 
(Labconco Corp., Kansas City, MO, USA) for 24 h at -70 °C and 0.02 mbar. 
 
2.3.9 STABILITY STUDY 
2.3.9.1 STABILITY OF STORAGE IN SUSPENSION FORM 
From our preliminary study, the nanosuspensions stored at 37 °C and room temperature 
were found not to be stable, so the effects of storage time on the chemical and physical 
stability of SEOA NS were investigated at 4 °C. Chemical stability was measured as the 
dissolved OA concentration changes in NS after storage at 1 month and 3 months intervals 
(after filtration) by HPLC. Physical stability was determined by the extent of particle size 
changes of SEOA NS after storage at 15 days and 30 days intervals. All experiments were in 
triplicates, and results averaged. 
 
2.3.9.2 OA STABILITY IN PLASMA 
SEOA4121 NS (SEL : SEP at 4 : 1, w/w; SE : OA at 2 : 1, w/w) was diluted with 60 x 
volumes of normal rat plasma, vortexed (1 min) and incubated in a shaking water bath (100 
rpm) at 37 °C. Samples were removed at 0, 1, 2, 4 and 24 h after incubation and centrifuged 
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(13,000 g x 10 min). Supernatant (50 μL) of each sample was removed and placed into a new 
tube. Ethyl acetate (1 mL) containing 1000 ng glycyrrhetinic acid (GA) as the internal 
standard (IS) was then added, vortexed (1 min) and centrifuged (13,000 g x 10 min). The 
supernatant was carefully removed, dried under nitrogen flow for 1 h at 40 °C and 
reconstituted in 1 mL methanol for LC-ESI-MS/MS measurement. The LC-ESI-MS/MS 
analysis method will be discussed in Section 2.3.13.3 Chromatography and tandem mass 
spectrometry analysis. All experiments were in triplicates, and results averaged. 
 
2.3.9.3 STABILITY IN SIMULATED GASTRIC AND INTESTINAL FLUIDS  
Non-enzyme simulated gastric fluid (SGF, pH 1.2) and simulated intestinal fluid (SIF, 
pH 6.8 and 7.4) were prepared following USP 29 (United States Pharmacopeia Convention, 
Inc., Rockville, MD, USA, 2006) with modification. SGF was prepared by dissolving 2 g of 
sodium chloride in 0.2 N hydrochloric acid and diluting with sufficient distilled water to 
make a 1000 mL solution and adjusting pH to 1.2 ± 0.1. SIF was prepared by dissolving 6.8 g 
of monobasic potassium phosphate in 250 mL distilled water, mixing and adding 77 mL of 
0.20 N sodium hydroxide. The resulting solution was adjusted with either 0.2 N sodium 
hydroxide or 0.2 N hydrochloric acid to pH 6.8 ± 0.1 and 7.4 ± 0.1 and made up with distilled 
water to 1000 mL. 
One millilitre SEOA4121 NS was separately diluted with 10 x volumes of SGF (pH 1.2) 
and SIF (pH 6.8 and 7.4), vortexed (1 min), and incubated in a shaking water bath (100 rpm) 
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at 37 °C. Samples were removed after 0, 0.5, 1, 2, 4 and 24 h incubation, and centrifuged 
(13,000 g x 10 min) and supernatant (50 μL) of each sample was transferred to a new tube for 
lyophilisation and subsequent dilution for HPLC analysis. All experiments were in triplicates, 
and results averaged. 
2.3.10 IN VITRO DISSOLUTION TEST 
Dissolution experiments were carried out using a dissolution apparatus (Model 2100c; 
Distek, North Brunswick, NJ, USA) according to the USP 29 Apparatus 2 (United States 
Pharmacopeia Convention, Inc., Rockville, MD, USA, 2006). The dissolution medium was 
500 mL pH 7.4 phosphate buffered saline containing 1 % sodium dodecyl sulphate (SDS), 
thermostated at 37 ± 0.5 °C with 100 rpm paddle rotating speed. SEOA 4121 NS, SEOA 
4121 NS lyophilized powder, OA coarse suspension (suspended in N,N-DMAC : PEG400 : 
water in the ratio of 2 : 4 :1, v/v/v) and SEOA4121 NS in dialysis bags (MWCO 2,000; 
Spectrum Medical Industries Inc, Singapore) were all added into the dissolution media, each 
bag contained an estimated amount equivalent to 8 mg OA. Samples (3 mL) were withdrawn 
at predetermined time intervals and filtered through 0.22 μm filters. After each withdrawal, 
an equal volume of the dissolution medium was added to maintain the volume constant. The 
content of dissolved OA was determined using HPLC. All dissolution experiments were 





2.3.11 CYTOTOXICITY OF OA AND SEOA NS 
A549 human NSCLC cells were cultured in F12 Ham Kaighn’s modification (F12K) 
medium, supplemented with 10 % FBS, 10 mM HEPES, 100 U/mL penicillin G and 100 
µg/mL streptomycin. The cells were maintained at 37 °C in a 5 % CO2 humidified incubator. 
To determine cytotoxicity of OA and SEOA NS, A549 cells were seeded in 96-well plates at 
a density of 6 x 10
3
 cells per well and incubated for 24 h at 37 °C in a 5 % CO2 humidified 
incubator. Culture media were then removed and replaced with 100 µL fresh media (blank) or 
fresh media containing 0.5 % Dimethyl sulfoxide (DMSO) (control) or different 
concentrations of OA (in media with 0.5 % DMSO) or SEOA NS or the same ratio blank SE 
NS without OA. After 24 and 72 h incubation, 10 µL MTT solution (5 mg/mL in Phosphate 
buffered saline (PBS)) was added to each well. After incubation at 37 °C for 4 h, the mixtures 
in the wells were removed, and 110 µL DMSO was added to each well and shaken at 100 
rpm for 30 min. Absorbance was measured using a multiplate reader (Molecular Devices, 
Sunnyvale, CA, USA) at 590 nm. Proliferation rate (%) was calculated as ((sample 
reading-blank reading) / (control reading-blank reading)) × 100. 
 
2.3.12 CELLULAR UPTAKE STUDY 
A549 cells (100,000 cells/mL) were seeded into each well of the 6-well plates (Falcon; 
Becton Dickinson, Sparks, MD, USA) and allowed to attach for 24 h. After cell attachment, 
the cell culture media were replaced with fresh media containing different concentrations of 
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SEOA NS. After incubation for 1 and 3 h respectively, the cells were washed thrice with cold 
PBS (4 °C, pH 7.4, 10 mM). The cells were then lysed by incubating with 0.2 mL cell lysis 
buffer (Cell Signaling Technology, Beverly, MA, USA). After brief sonication on ice, the 
cell lysates were processed to determine the OA levels by LC-ESI-MS/MS using a modified 
published method (28, 115), which will be elaborated in Section 2.3.13.3 Chromatography 
and tandem mass spectrometry analysis. 
To determine the levels of cellular uptake of NS, 5 μL of glycyrrhetinic acid (GA) 
solution (1 μg/mL) as the internal standard (IS) was added to 50 μL of cell lysate sample, and 
vortexed for 1 min. The samples were extracted with ethyl acetate (900 μL) by vortex-mixing 
(1 min) and centrifuged (13,000 g x 10 min) at room temperature. The organic layer was 
carefully transferred and dried under nitrogen flow at 40 °C. The residues were dissolved in 
methanol and transferred to clean vials for sample injection. Calibration standards were 
prepared with 50 μL blank cell lysate sample by the same method. Cell protein was assayed 
by BCA Protein Assay Kit (Thermo Fisher Scientific, Waltham, MA, USA) according to the 
kit protocol. Results were expressed as amount (μg) of OA per mg total cell protein.  
To study the effect of temperature on SEOA NS uptake, as control groups, A549 cells 
were pre-incubated in regular growth medium at 4 °C for 30 min and co-incubated with 
SEOA NS (15 μg/mL) at 4 °C for 3 h. Normal groups were pre-incubated in regular growth 
medium at 4 °C for 30 min then co-incubated with SEOA NS (15 μg/mL) at 37 °C for 3 h. 
The dose and time effects on cellular uptake of NS were also examined. To study the 
dose-dependent NS uptake effect, cells were incubated with different concentrations of NS 
(15 and 30 μg /mL) for 1 h. To study the time-dependent NS uptake effect, cells were 
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incubated with NS (15 μg/mL) for 1 and 3 h. 
 
2.3.13 PHARMACOKINETICS STUDY 
2.3.13.1 INTRAVENOUS AND ORAL ADMINISTRATION OF OA TO RATS 
The study design and animal handling protocol of this pharmacokinetic study were 
modified from our previous study (131) and approved by the Institutional Animal Care and 
Use Committee of the National University of Singapore. Adult male Sprague–Dawley rats 
(250 – 300 g) were purchased from the Laboratory Animal Centre of the National University 
of Singapore. The rats were housed under temperature (22 ± 1 °C) and relative humidity (60 
– 70 %) controlled environment in Animal Holding Unit of the university operated at a 12-h 
light / dark cycle. The rats were given free access to food and water before surgery. On the 
day before the pharmacokinetic study, a polyethylene tube (i.d. 0.58 mm, o.d. 0.965 mm, 
Becton Dickinson, Sparks, MD, USA) was placed into the right jugular vein through surgical 
implant under anaesthesia. The intravenous (iv) drug administration and blood sample 
collection were performed through this cannula. The rats were randomly divided into four 
groups (n = 5 per group). Group I received iv administration of OA while three other groups 
received oral dosing through gavages. It is known that oral absorption may be influenced by 
different dietary regimens and the inherent bile salt solubilisation capacity in the intestine. 
Hence, the rats for oral administration (Groups II – IV) were kept in fasting condition 
overnight prior to the oral gavages and during blood collection but free access to water were 
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allowed. However, such restriction was not applied to the rats that received iv administration. 
Rats in Groups II and III were administered single dose of SEOA 4121 NS by oral gavages at 
the dose of 10 and 20 mg/kg, respectively. As controls and comparisons, rats in Groups I and 
IV would receive either SEOA4121 NS by iv administration (2 mg/kg) or oral administration 
of coarse OA suspensions in N, N-DMAC : PEG400 : water (2 : 4 : 1, v/v/v) at the dose of 20 
mg/kg. Serial blood samples (200 μL) were collected from each animal at 1, 5, 15, 30, and 45 
min, and 1, 1.5, 2, 3, 4, 6, 8, 10 and 12 h after iv administration and at 5, 15, and 30 min, and 
1, 1.5, 2, 3, 4, 6, 8, 10 and 12 h after oral administration. The cannula was flushed and blood 
was replaced by an equivalent volume of heparin–saline (20 IU/mL heparin in normal saline) 
after each draw of blood sample. Plasma samples were collected after centrifugation (3,000 g 
x 5 min) of the blood samples and stored at −80 °C until LC-ESI-MS/MS analysis. 
 
2.3.13.2 SAMPLE PREPARATION AND CALIBRATION  
The sample preparation method (liquid-liquid extraction) was adopted from our previous 
study with minor modification (131). The plasma sample (100 μL) was spiked with methanol 
solution (5 μL) of GA (20 μg/mL) as IS and mixed briefly in a clean 2 mL centrifuge tube. 
Then ethyl acetate (300 μL) was added to the tube and mixed for 1 min to facilitate the 
extraction procedure. After this liquid-liquid extraction, the tube was centrifuged (13,000 g x 
10 min) and the ethyl acetate layer was carefully transferred to another clean tube. The 
extraction procedure was repeated for two additional cycles and the ethyl acetate layer was 
collected in the same tube. The sample was then dried under nitrogen flow at 40 °C. The 
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residue was reconstituted with methanol (75 μL) and centrifuged (13,000 g x 5 min). The 
supernatant was injected (10 μL) into the HPLC column. Calibration standards were prepared 
with 100 μL blank plasma samples using the same procedures. The calibration curve was 
obtained from the samples prepared by spiking OA and internal standard into pooled rat 
plasma. It was linear (r
2
 = 0.9907) within the range of 20–2,000 ng/mL of OA. 
The within-day and between-day accuracy and precision were evaluated at three 
concentration levels (40, 100, and 800 ng/mL) based on five measurements carried out in a 
single day and over five days of validation period, respectively, according to previous report 
with modifications (115). The accuracy was expressed as bias (the percentage of difference 
between the measured and spiked concentrations over that of the spiked value), whereas the 
precision was presented as the relative standard deviation (R.S.D. %). The absolute recovery 
of the extraction was determined by comparing the peak area obtained from the plasma 
sample with peak areas obtained by the direct injection of pure OA standard solutions in the 
HPLC column at three different concentration levels. The quantification of the chromatogram 
was performed by using peak area ratios of OA to internal standard. 
 
2.3.13.3 CHROMATOGRAPHY AND TANDEM MASS SPECTROMETRY 
ANALYSIS 
The concentrations of OA in plasma were determined by a previously reported 
LC-ESI-MS/MS method with modifications (28, 115). Briefly, the HPLC system was an 
Agilent 1100 series machine equipped with a G1312A binary pump and a G1379A degasser 
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(Agilent, Palo Alto, CA, USA). The HPLC column was a C18 column (300 mm × 2. mm i.d.) 
packed with 3 μm ODS stationary phase (Hypersil Aquasil, Thermo Scientific, Waltham, MA, 
USA) which was protected with a guard column (Inertsil ODS-3; GL Sciences, Tokyo, 
Japan). The HPLC mobile phase consisted of acetonitrile/10 mM ammonium acetate buffer 
pH 6.5 (15 : 85, v/v). The flow rate was set at 0.30 mL/min and analysis was performed in 
isocratic mode. The mass spectrometer was the Qtrap 3000 model with an electrospray 
ionization (ESI) interface (Applied Biosystems, Toronto, Canada). Negative ion ESI with the 
collision energy -30 V, curtain gas 10 psi and ion source temperature 200 °C were used. 
Quantification was performed with multiple selected reaction monitoring (MRM) mode. The 
transition of OA is 455.5/455.5 (m/z) (Figure 2.10a) and GA (IS) is 469.5/425.5 (m/z) (Figure 
2.10b) with a scan time of 100 ms per transition. 
 
2.3.13.4 RESULTS ANALYSIS 
WinNonlin standard Version 5.01 (Scientific Consulting Inc., Apex, NC, USA) was 
used to analyze the pharmacokinetic parameters and non-compartmental model was adopted 
for the analysis. The area under the plasma concentration (AUC) versus time curve (AUC0→t) 
in rats that received oral administration (Groups II – IV) was calculated by the linear 
trapezoidal rule with the time point from 0 to the last detectable time point, whereas the 
AUC0→t in rats that received iv dosing (Group I) was calculated through the same rule except 





. Absolute bioavailability (F %) of OA after oral administration (Groups II – 
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IV) was calculated using the following equation: 
0 t
0 t
AUC (GroupII, IIIor  IV)
Dose(GroupII, IIIor  IV)
F% 100




  . 
 
2.3.14. STATISTICAL ANALYSIS 
Results were presented as mean ± standard deviation (std). Statistical significance of the 
results was analysed using two-tail independent sample t-test or one-way ANOVA. Values of 
p<0.05 were considered statistically significant. 
 
2.4. RESULTS AND DISCUSSION 
2.4.1 CHARACTERISTICS OF SEOA NS 
2.4.1.1 CRITICAL MICELLAR CONCENTRATION (CMC) OF SEL AND SEP 
To determine the concentration of SE in preparing SEOA NS by emulsion-organic 
solvent evaporation method, the CMC values of SEL and SEP needed to be confirmed. 
Figure 2.2 shows the surface tension readings of SEL and SEP solutions (mN/m) as a 
function of the concentrations of the surfactant (%, w/v). From the tendency equations, CMC 
of SEL and SEP were calculated to be 0.021 (%, w/v) and 0.00105 (%, w/v), respectively. 





































Figure 2.2 Determination of CMC of SEP (a) and SEL (b) by surface tension method. X 
axis represents the concentrations of the surfactant (%, w/v) and Y axis shows the 
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2.4.1.2 PARTICLE SIZE AND PDI OF DIFFERENT SEOA NS  
The size and PDI of SE-OA NS were characterized by DLS measurement. Figure 2.3 
shows a typical size distribution curve of OA NS prepared with SEL and SEP. The graph 
shows the distribution of particle sizes, with the mode of particles around 100 nm. With the 
exception of SEOA9121 NS (SEL : SEP at 9 : 1, w/w; SE : OA at 2 : 1, w/w) (p<0.01), 
which had a mean size of 171.40 nm, the mean size of all other particles were all at around 
100 nm in mean size. The PDI values were generally relatively high. SEOA 4121 NS and 
SEOA 9121 NS had the smallest PDI readings of around 0.41 (see also Table 2.2). 
As indicated in Table 2.2, it was noted that the weight ratio of SEL to SEP may had 















Figure 2.3 Representative particle size distribution data obtained from Zetasizer 

















Table 2.2 Comparison of SEOA NS properties 
 
 
Data represent 3 independent experiments repeated in triplicate. Values are presented as 
means ± std. Statistics are carried out via one-way ANOVA. 
a
, significantly different 
compared with SELOA (p<0.05). 
b
, significantly different compared with SEPOA (p<0.05). 
c
, 
significantly different compared with SEOA91101 (p<0.05). 
d
, significantly different 
compared with SEOA4121 (p<0.05). 
e
, significantly different compared with SEOA9121 
(p<0.05). 
f
, significantly different compared with SEOA9151 (p<0.05). 
g
, significantly 
different compared with SEOA4151 (p<0.05). 
h




Among all the formulations, when the ratio of SEL to SEP equalled to 9 : 1, the particle 
size was found to be the largest. For instance, between SEOA 4121 and SEOA 9121, which 
only differed from the SEL to SEP weight ratios, the latter was found to contain much larger 
nanoparticulates. The conditions were about same with SEOA 2151(SEL : SEP at 2 : 1, w/w; 
SE : OA at 5 : 1, w/w), SEOA 4151(SEL : SEP at 4 : 1, w/w; SE : OA at 5 :1, w/w) and 
Group Size  
(nm) 
PDI EE % Saturation 
solubility 
(mg/mL) 
SELOA 101.60 ± 4.00 
e, f
 0.60 ± 0.09
d,e 
79.40 ± 0.06
 d, e, f, g, h 
0.66 ± 0.01
 d, g, h 
SEPOA 92.20 ± 2.10 




 d, e, f, g, h 
0.67 ± 0.03
 d, g, h 




. 79.29 ± 2.69
 d, e, f, g, h 
0.66 ± 0.02
 d, g, h 
SEOA9121 171.40 ± 3.40 
a, b, c, d, 




 a, b, c, d, f, 
g, h 
0.75 ± 0.02
 d, g, h 
SEOA9151 133.70 ± 1.20 
a, b, c, d, 




 a, b, c, e, g, 
h 
0.68 ± 0.05
 d, g, h 
SEOA4121 96.60 ± 2.30 




 a, b, c, e 
1.89 ± 0.08
 a, b, 
c,e,f, g, h 
SEOA4151 93.10 ± 1.50 




 a, b, c, e, f 
0.91 ± 0.01
 a, b, c, 
d, e, f 
SEOA2151 110.60 ± 6.80 





 a, b, c, e, f 
0.82 ± 0.04
a, b, c, 
d, e, f 
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SEOA 9151(SEL : SEP at 9 : 1, w/w; SE : OA at 5 : 1, w/w). These findings suggested at the 
above surfactant ratio (SEL : SEP at 9 : 1, w/w), the particles of SEOA NS were probably 
coated by much thicker surfactant layers, hence demonstrating larger particle sizes. 
 
2.4.1.3 MORPHOLOGY DETERMINATION BY TEM 
Confirmation of the NS size and morphology of SEOA NS were carried out using 
transmission electronic microscopy (TEM). Figure 2.4 shows examples of the TEM 
photomicrographs of SEOA NS. The constituent OA particles were generally spherical in 
shape with a mean diameter of around 30-40 nm. The smaller particle size estimated as 
compared with the results obtained using the DLS may be due to nano-aggregation effects 
and aggregates were seen during DLS measurements. Particles of NS tended to aggregate 
together due the their high surface energies and observations by the DLS methods only give 
the actually presented average size distribution which comprised considerably of the 
nanoaggregates, and the lesser isolated individual nanoparticles. TEM results showed the 
particles presented mainly as clustered agglomerates, encapsulated by distinct SE 
membrane-like layer, which appeared like an “outer shell”. This outer shell may function as a 











Figure 2.4 Representative TEM of SEOA-NS produced by emulsion-organic solvent 
evaporation method. (c=encapsulated OA; d= thickness of SE coating) 
 
2.4.1.4 FREE OA EQUILIBRIUM AQUEOUS SOLUBILITY AT 25 °C, SEOA NS 
ENCAPSULATION EFFICIENCY (EE) AND SATURATION SOLUBILITY  
After the determination of the size and morphology of the SEOA NS, studies were next 
carried out to (a) compared the EE % of NS prepared with either pure SE or mixture of 
different ratios of SE types, combined at predetermined weight ratios and (b) study which of 
the formulations of NS gave rise to the highest OA saturation solubility. 
The HPLC peak for OA was detected at a retention time of about 6.8 min, using the 
above mentioned settings, and SE did not have any significant effect on the separation of OA 
since the elution peak of SE merged with that of organic solvent, and occurred at the early 
elution phase. The concentrations of unknown OA samples can be determined by reference to 
the standard curve (Figures 2.5a and b). The intra-day coefficients of variation were 1.24, 
1.86 and 3.55 % respectively, the inter-day coefficients of variation on three consecutive days 







mean deviation of all concentrations from theoretical value, were 1.43 %, 0.83 % and 1.06 % 
for OA respectively. 
Since free OA equilibrium aqueous solubility was too low to be detected directly, the 
OA aliquot obtained from the equilibrium aqueous solution was freeze dried and concentrated 
in methanol solution before use for HPLC detection. From the results obtained by HPLC, 
equilibrium solubility of OA in water at 25 °C was found to be approximately 3.43 ± 0.11 
(µg/mL), which is close to the value reported by Chen et al. (4.37 µg/mL) (27). 
From Tables 2.2 and 2.3, of all the SEOA NS, SEOA4121 NS preparations had much 
higher OA saturation solubility, at about 1.89 mg/mL, which is almost 550 folds higher than 
free OA solubility in water. Meanwhile, SEOA91101 NS showed the highest percent 
encapsulation efficiency (79.29 %) as well as possessing the highest level of product stability. 
Upon consideration of these observations, it was decided that these two SEOA formulations 









































Figure 2.5a HPLC chromatogram of OA showing OA retention time is approximately 6.8 
min. 2.5b Calibration curve of OA standards: 0.02, 0.04, 0.06, 0.08, 0.1, 0.2, mg/mL; R2 
=0.9983. X axis indicates OA concentration (mg/mL), Y-axis indicates UV absorption. 
 
According to Ostwald-Freundlich’s equation (44), log (Cs/Cα) = 2σV/ (2.303RTρr), 
where Cs is the saturation solubility, Cα is the solubility of the solid consisting of large 
particles, σ is the interfacial tension of substance, V is the molar volume of the particle 
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material, R is the gas constant, T is the absolute temperature, ρ is the density of the solid and 
r is the radius. By decreasing the particle size (r), NS should show an increase the saturation 
solubility (Cs) of OA. Comparing with a previous report by Chen et al. (27), the saturation 
solubility increased by 191 to 550 folds when SE stabilized, and SE was much more effective 
than the 6 folds increase by polysorbate 80. This is the first report on the use of SEL and SEP 
to stabilized NS.  
From the chemical structure, SEL has a shorter fatty acid chain than SEP. According to 
the literature and in the product manufacturer’s manual, SEL is listed as being more 
hydrophilic than SEP, with smaller logP value (1.5 vs. 3.2) (118, 119) and a higher HLB 
value( 13 vs. 15). Stabilization of NS with the combination of SEL and SEP could produce 
synergistic advantages as the combined properties of both surfactants could bring about 
improved affinity of the SE to the hydrophobic drug and resultant NS stabilized by SE are 
more readily dissolving in aqueous solution. It would also be expected that the 
complementary nature of these two SEs should lead to the formation of a more stable NS. 
Indeed, when the surfactant to drug ratio (10 : 1) was kept constant for SELOA NS (SEL : 
OA at 10 : 1, w/w), SEPOA NS (SEP : OA at 10 : 1, w/w) and SEOA91101 NS (SEL : SEP 
at 9 : 1, w/w; SE : OA at 10 : 1, w/w), the three OA NS formulations all exhibited similar 
values in their mean particle sizes, encapsulation efficiency and OA solubility. However, 
SEOA91101 NS was more stable upon prolonged storage than SELOA and SEPOA. (Table 
2.2). 
The weight ratios of surfactant (SEL and SEP) to OA may have influenced the NS 
characteristics. As shown in Table 2.2, when the SEL : SEP weight ratios were kept constant 
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and the amount of OA to SE was increased (from 10 : 1 to 2 : 1) for the three OA NS (SEOA 
91101, SEOA9151, and SEOA9121), it resulted in an increase in the particle size (from 
103.60 nm to 171.40 nm) and OA saturation solubility, but a decrease in the EE % (from 
79.29 % to 18.07 %) and stability (Tables 2.2 and 2.3). The findings indicated that additions 
of OA at low OA concentrations brought about an increase in the saturation solubility of SE 
stabilized OA NS, but it did not keep on increasing and beyond a level, further OA increase 
was at the expense of sacrificing encapsulation efficacy and stability. Since the overall 
amount of SE was constant for all the formulations, the increase of OA beyond the stabilizing 
ability of SE may probably caused the decrease in the EE % and stability.  
 
2.4.1.5 FT-IR 
From TEM findings, nanoprecipitated particles of OA were observed to be encapsulated 
by SE membranes. Thus, it may be pertinent to examine the possibility of any interaction of 
SE with the hydrophobic drug. The SE OA samples were examined by determining the FT-IR 
spectra. According to Figure 2.6, all of the major peaks of OA remained clearly seen in the 
lyophilized SEOA NS, thus, indicating that OA was not chemically modified when 







Figure 2.6 FTIR spectra of pure oleanolic acid (A), lyophilized SEOA4121 NS (B), and 



























Table 2.3 Chemical and physical stability of SEOA NS 
 
Group Original (%) 1 month relative 
concentration (%) 
3 month relative 
concentration (%) 
15 days size 
change (%) 
 30 days size 
change (%) 
SEOA4151 100.00 82.52 ± 1.63
e 
67.75 ± 0.56
c, e, g 
16.58 ± 3.20 
b, c, d, g, h 
124.97 ± 17.76 
e, g, h 
SEPOA 100.00 86.32 ± 1.12
e 
65.35 ± 0.70
c, e, g 
64.49 ± 13.30 
a, e, f 
121.79 ± 59.99 
e, g, h 
SEOA2151 100.00 88.50 ± 1.81
e 
82.24 ± 0.79
a, b, g, h 
53.11 ± 21.38 
a, e, f 
93.10 ± 32.37 
d, g, h 
SELOA 100.00 88.27 ± 4.79 
e 
76.79 ± 0.33 
g 
47.79 ± 6.57 
a, e, f 
172.06 ± 28.89 
c, e, g, h 
SEOA91101 100.00 98.61 ± 4.44 
a, b, c, d, 
f, g, ,h 
88.21 ± 1.30 
a, b, f, g, 
h 
4.89 ± 1.47 
b, c, d, g, h 
39.03 ± 24.41 
a, b, d, f, g, h 




13.54 ± 17.98 
b, c, d, g, h 
153.27 ± 26.16 
e, g, h 
SEOA9121 100.00 80.54 ± 2.97 
e 
44.88 ± 0.06
a, b , c, d, 
e, f, h 
57.28 ± 16.93 
a, e, f 
376.37 ± 23.31 
a, b, c, d, e, f 
SEOA4121 100.00 87.06 ± 4.86 
e 
68.17 ± 0.70
c, e, g 
43.74 ± 11.44 
a, e, f 
403.93 ± 47.80 
a, b, c, d, e, f 
 
Data represent 3 independent experiments repeated in triplicate. Values are presented as 
means ± std. Statistics are carried out via One-Way ANOVA. 
a
, significantly different 
compared with SEOA4151 (p<0.05). 
b
, significantly different compared with SEPOA 
(p<0.05). 
c
, significantly different compared with SEOA2151 (p<0.05). 
d
, significantly 
different compared with SELOA (p<0.05). 
e
, significantly different compared with 
SEOA91101 (p<0.05). 
f
, significantly different compared with SEOA9151 (p<0.05). 
g
, 
significantly different compared with SEOA9121(p<0.05). 
h










2.4.1.6 STABILITY OF SEOA NS 
Table 2.3 demonstrates the comparison of stability values among the SEOA NS. It is 
noted that most of the NS samples were found to be relatively chemical stable (>80 %) for 1 
month when stored at 4 °C but much degraded after 3 months’ storage. SEOA 91101 NS and 
SEOA 2151 NS were found to be more chemically stable than other NS formulations. Among 
all the NS, SEOA91101 NS was the most stable, in both physical and chemical stability 
aspects. Since SEOA 4121 NS was stable up to 15 days of storage and with the highest OA 
content, it was hence selected for further in vitro study and in vivo pharmacokinetics 
application. From Tables 2.4 and 2.5, either in rat plasma or in SGF and SIF circumstances, 
SEOA4121 NS was shown to be relatively stable over the first 24 h in vitro. 
 
Table 2.4 SEOA 4121 NS incubation with rat plasma 
 
Time(h) Relative Concentration (%) Standard (%) 
0 100.00 0.00 
1 96.94 9.63 
2 88.99 1.95 
4 89.91 10.38 
24 83.94 5.05 















Table 2.5 SEOA 4121 incubated in SGF and SIF 
 
 
Data represent 3 independent experiments repeated in triplicate. Values are presented as 
means ± std 
 
2.4.2 IN VITRO DISSOLUTION 
In the preparation of a dosage form, it is important that the bioactive compound remains 
bioavailable upon ingestion into the gastrointestinal tract. The common assessment of 
bioavailability in vitro of a drug delivery system is by the use of the dissolution test method 
as prescribed by the USP. The dissolution rate of OA was determined by the in vitro 
dissolution profiles of different OA formulations (Figure 2.7a). The dissolution rate of OA 
coarse suspension (suspended in N, N-DMAC : PEG400 : water at 2 : 4 :1, v/v/v) was very 
  Sample Time (h) 
  0.5 1  2  4 24 
Media  Relative Concentration (%) 
































low, only about 15 % of the drug dissolved in 120 min. On the contrary, the SEOA 4121 NS 
either in suspension form or in lyophilized powder form both showed a great increase in the 
dissolution of OA over the coarse suspension, and 100 % of OA dissolved within 120 min. 




 (132), where, 
dW
dt
 is the rate 
of dissolution, A is the surface area of the solid, C is the concentration of the solid in the bulk 
dissolution medium, Cs is the concentration of the solid in the diffusion layer surrounding the 
solid, D is the diffusion coefficient, and L is the diffusion layer thickness. 
An increase in saturation solubility (Cs) and decrease in particle size would led to 
increased dissolution rate (
dW
dt
). Thus, formulating the poorly water-soluble drug as 
nanosize particles had a dramatic effect on both its saturation solubility and dissolution rate, 
and the bioavailability could be consequently increased.  
The fast dissolution of OA from SEOA 4121 NS may be derived from the release of OA 
as free dissolved molecular form or in NS form. Therefore, the dialysis bag, through which 
only free OA can pass, was needed to identify the different forms released. From Figure 2.7b, 
using the dialysis method, no free OA could be detected even after 6 h in the dissolution 
medium and the dissolution rate increased very slowly. The percent of dissolved OA did not 
reach 12 % even after 48 h. The present findings indicated that most of the dissolved OA 












Figure 2.7 Dissolution profiles of OA coarse suspension (▲) (suspended in N,N-DMAC : 
PEG400 : Water at 2 : 4 : 1, v/v/v), SEOA 4121 NS (■) and SEOA 4121 lyophilized 
powder(▴) (2.7a) and SEOA4121 NS in dialysis bag (▲) (2.7b) in pH 7.4 phosphate 












































2.4.3 CYTOTOXICITY OF SEOA NS  
   In NS form, the saturation solubility of OA was increased markedly from 3.43 
µg/mL (free OA) to 660 µg/mL (SEOA91101 NS) and 1890 µg/mL (SEOA4121 NS). Owing 
to the increase in OA saturation solubility, the in vitro cytotoxicity in A549 cell lines as 
determined by the MTT assay also saw an increased. As shown in Figure 2.8, formulation of 
SE-stabilized OA NS significantly increased the cytotoxicity of OA in both time- and 
dose-dependent manner (see data in Table 2.6). The 72 h IC50 dropped from 120 µM of free 
OA to 26 µM of SEOA4121 NS and 18 µM of SEOA91101 NS. Although free OA is not 
considered as potent in anti-lung cancer cells, formulated OA as NS form showed much 
enhanced bioefficacy even without any chemical modification.  
The enhanced cytotoxic effect was most likely to be due to the increased saturation 













Table 2.6 IC50 comparison of SEOA NS and free OA 
 
 
IC50 values were calculated by nonlinear regression (curve fit) of cytotoxicity data in 
figures 2.8a-d using sigmoidal dose response (variable slope) equation, Graphpad Prism 


























Group 24h (µg/mL) 72h (µg/mL) 
Free OA 59. 67 ± 1.01(130.00 µM) 56.75 ± 1.02 (120.00 µM ) 
SEOA91101 NS 13.10 ± 1.08 (28.00 µM ) 8.30 ± 1.05 (18.00 µM ) 
SEOA4121 NS  12.10 ± 1.09 (26.00 µM ) 
SE(4 : 1) NS 211.40 ± 1.03 217.10± 1.03 



























































































































Figure 2.8 Dose- and time-dependent growth inhibition of A549 cells by (a) Free OA 
dissolved in media containing 0.05 %DMSO, (b) SEOA91101 NS (*, p<0.05 between 24 h 
and 72 h) (c) SEOA4121 NS(*, p<0.05 between 24 h and 72 h) (d) blank SE 41 NS (SEL : 
SEP at 4 : 1 w/w) and blank SE 91 NS (SEL : SEP at 9 : 1 w/w) without OA. *, p<0.05 
between SE41 24 h and SE41 72 h; #, p<0.05 between SE91 24 h and SE91 72 h. Data is 






























This contention was supported by the findings that treatment of A549 cells with 
drug-free NS resulted in a considerably much less cytotoxic effect than when the cells were 
treated with drug-loaded SEOA NS.  
Since the encapsulation efficiency of SEOA 4121 NS and SEOA 91101 NS was 45.38 % 
and 79.29 % respectively (Table 2.6), without considering the loss of SE during preparation, 













At 72 h after the treatment, the IC50 of NS prepared with SEL : SEP weight ratio at 4 : 1 
was 17.57 times that of SEOA4121 NS (more than 4.41 times). Similarly, the IC50 of NS 
prepared with SEL : SEP weight ratio at 9 : 1 was 19.02 times that of SEOA91101 NS at 24 h 
and 25.61 times at 72 h after treatment (more than 12.61 times).These observations indicated 
that the cellular toxic effect of SEOA NS was mainly derived from the nanoparticulate drug 
rather than from the surfactants that formed and stabilized the NS (see Table 2.6). 
 
2.4.4 CELLULAR UPTAKE OF SEOA NS  
LC-ESI-MS/MS was used to quantify the cellular OA concentration. The mass peak of 
OA was demonstrated in Figure 2.9a. Using the pre-determined settings, the GA (internal 
stand) peak and OA peak emerged at around 2.20 min and 4.29 min respectively.  
Suitable temperature, around 37ºC, is crucial for intracellular metabolism (133). When 
A549 cells were incubated at 4ºC, cellular uptake of SEOA NS was significantly lower than 
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that at 37ºC (Figure 2.9b). Our results suggested that uptake of SEOA NS into the A549 cells 
required suitable temperature. To determine the effect of varying the NS concentration and 
incubation time on uptake of NS by the A549 cells, the cells were treated with different OA 
concentrations (15 μg/mL or 30 μg/mL) for same incubation time (1 h) or same OA 
concentration (15 μg/mL) for different times (1 h or 3 h). As shown in Figures 2.9c and d, 
significantly higher uptake of SEOA NS compared to control was observed when the cells 
were treated with a higher concentration of OA or longer incubation time. This may explain 
that SEOA 4121 NS and SEOA 91101 NS had better cytotoxicity effect than free OA and 
they yielded better effect after 72 h incubation. 
From the in vitro dissolution study, it was demonstrated that most of the dissolved OA 
existed as NS droplets and not as the free molecular form. This may imply that the uptake of 
OA was mainly in NS form, and by endocytosis.  
However, further experiments will be needed to verify this hypothesis and to explore the 
underlying mechanism for OA intake as well as to study the full extent of in vivo bioeffect of 



















































































































Figure 2.9 Cellular uptake of SEOA NS.  (a) Mass peak of OA by LCMS. The left peak 
is the internal standard and the right one is OA peak. Cellular uptake of SEOA NS is (b) 
temperature-dependent, (c) concentration-dependent, and (d) time-dependent. Data is 
presented as mean (µg/mg protein.mL) ± Std from three independent experiments 
repeated triplicate. *, p<0.05; **, p<0.01. 
 
2.4.5 SEOA NS PHARMACOKINETICS PROFILE 
2.4.5.1 RECOVERY, PRECISION AND ACCURACY IN ANALYSIS OF PLASMA 
SAMPLES 
The LC-ESI-MS/MS system enabled a sensitive and well-defined separation between 
the drug, internal standard and endogenous components. LC-ESI-MS/MS peaks of OA and 
GA are shown in Figure 2.9a. The mass spectra of [M-H]
-
 of OA and GA were indicated in 
Figures 2.10a and b, respectively. Figure 2.11 indicates the calibration standard cure of OA. 
It was linear (R
2
 = 0.9942) within the range of 20–2,000 ng/mL. From Table 2.7, the absolute 
recoveries of OA from the plasma were more than 84.30 %, indicating that most of the OA 
introduced in the plasma samples were extracted. The within-day and between-day precision 
(R.S.D. %, n = 5) for the OA spiked control samples at 40, 100, and 800 ng/mL levels varied 
between 2.50 and 11.20. The corresponding within-day and between-day accuracy (bias %, n 




2.4.5.2 PHARMACOKINETICS RESULTS AFTER INTRAVENOUS 
ADMINISTRATION 
Figure 2.12a shows the pharmacokinetics results of OA following single iv bolus dose 
(2 mg/kg) of NS (Group I). The findings demonstrated that the plasma concentration of OA 
declined rapidly over the first hour and was followed by a slower decline from 2 h onwards. 
The maximum plasma concentration (Cmax) was high (21.98 ± 5.79 μg/mL) and plasma 
elimination half-life (T1/2) was found to be 88.41 ± 16.15 min. AUC and Cl values were 
calculated as 121.49 ± 27.37 μg.min/mL and 17.11 ± 3.67 mL/min/kg, respectively. 
2.4.5.3 PHARMACOKINETICS RESULTS AFTER ORAL ADMINISTRATION 
The plasma pharmacokinetic profiles and the pharmacokinetic parameters following 
single oral dose of SEOA NS (10 and 20 mg/kg) and OA coarse suspensions (20 mg/kg) are 
shown in Figure 2.12b and Table 2.8. 

















40 86.40 6.50 5.60 -8.30 11.20 -12.00 
100 94.70 2.10 4.90 5.90 4.00 3.80 
800 84.30 1.30 2.50 6.50 1.90 -5.80 
 
Bias %=[(concentration added-concentration found)/concentration added]×100 
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Table 2.8 Oral pharmacokinetics profiles of SEOA NS and coarse suspension 
 
 
Parameter Group II Group III Group IV 
Formulation NS NS Suspension 
Dose (mg/kg) 10.00 20.00 20.00 
AUC (μg.min/mL) 21.35 ± 3.89 a, c 44.06 ± 7.25 a, b 6.74 ± 3.42 b, c 
Tmax (min) 13.00 ± 4.47 21.00 ± 8.22 13.00 ± 4.47 
Cmax (ng/mL) 397.35 ± 170.19 
a, c 
817.19 ± 255.21 
a, b
 69.95 ± 42.71
 b, c 
T1/2 (min) 76.38 ± 38.19 78.06±29.21 102.10±16.56
 




Data is presented as Mean ± Std, N=5.
a
, p<0.05 between Group II and III; 
b
, p<0.05 between 
III and IV; 
c





























Figure 2.10 Mass spectra of [M-H]
-
 of oleanolic acid (a, OA) and glycyrrhetinic acid (b, 












In all cases, OA in NS groups resulted in a significantly (p<0.05) higher Cmax than the 
suspension formulations. However, there were no significant differences (p>0.05) in Tmax and 
T1/2. In all groups, the NS group (Groups II and III) had a significantly higher bioavailability 
(F %) values (6 to 7 folds higher) than the suspension group (Group IV) (p<0.05) while for 
between 10 mg/kg and 20 mg/kg NS groups, there was no statistically significant differences 
(p>0.05). These findings indicated that the dosage form of OA affected the extent of its oral 
absorption. Figure 2.12b indicates that the plasma concentration of OA declined rapidly over 
the first stage and was followed by a second peak at 2 h, 3 h and 4 h for Group IV, Group III 
and Group II respectively, which was probably due to the enterohepatic recirculation of OA. 
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Oral bioavailability of a drug is dependent on various factors including the stability of 
the ingested drug in the gastrointestinal (GI) tract, its aqueous solubility, its permeability 
through the intestinal membrane and the first-pass elimination rate (134). A report by Jeong 
et al. (28) suggested that the low oral bioavailability of OA suspension may be due to its poor 
solubility, poor gastrointestinal absorption (by Caco-2 cell permeability model) and hepatic 
first-pass metabolism. However, in the present in vivo pharmacokinetic study, the findings 
indicated that the bioavailability of OA was highly enhanced by the NS formulation. Among 
all the NS formulations studies, the selected SEOA 4121 NS had encapsulated the highest 
amount of OA, demonstrated to possess relatively good in vitro stability in rats’ plasma, SGF 
and SIF for 24 h, and shown to produce increased in vitro dissolution rate. The NS 
formulation produced could not only enhance the saturation solubility and dissolution rate of 
OA but also augmented its bioavailability and provided some protection against breakdown 

























Figure 2.12 Mean plasma concentration-time profiles comparison of OA in rats after (a) 
IV injection at 2 mg/kg (■,n=5), (b) oral administration of OA NS at 10 mg/kg (○, n=5), 
20 (■, n=5) mg/kg doses and oral administration of OA coarse suspension (△, n=5, 























































NS of OA can be prepared by emulsion-organic solvent evaporation method using SEL 
and / or SEP as stabilizing surfactants. Mean particle sizes of most SEOA NS were around 
100 nm. They were chemically and physically stable under short-term storage. The different 
weight ratios of SEL to SEP and SE to OA influenced the characteristics of SEOA NS. These 
NS particles were usually found to form clustered agglomerates and each sub-units were seen 
to be covered by distinct SE coating on the periphery. Preparation of OA as NS increased its 
saturation solubility considerably. With a huge surface area to volume ratio, the saturation 
solubility of resultant SEOA particles ranged from 0.66 mg/mL (SEOA91101 NS) to 1.89 
mg/mL (SEOA4121 NS), which were of 191 to 550 folds increase over free OA. SEOA NS 
increased the OA dissolution rate markedly. Most of the dissolved OA existed in the NS 
particulates and not in the free dissolved molecular form. Formulation of OA as NS 
significantly and substantially increased the cytotoxicity of OA. Both SEOA91101 and 
SEOA4121 reduced the proliferation rate of A549 cell lines to a much greater extent than free 
OA. This increased activity was attributed to the nanonized drug and not the SE. Cellular 
uptake of SEOA NS by A549 cells was shown to be a temperature-, concentration- and time- 
dependent process. NS of OA not only increased its saturation solubility and dissolution rate 
to a great extent but also change the pharmacokinetic profile of OA after oral administration. 
Oral bioavailability of OA was enhanced by the NS formulation, which showed much higher 
Cmax and F % (6 to 7 times increase) than the coarse suspension group. Dose-independent 
pharmacokinetics of OA was observed after oral administration in the range of 10 to 20 
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mg/kg. However, the cellular uptake mechanism and in vivo bioeffect of SEOA NS still 






























CHAPTER 3. DEVELOPMENT AND EVALUATION OF 
SEOA NS VIA WET BALL MILLING OPTIMIZED BY 
DESIGN OF EXPERIMENTS (DOE) 
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CHAPTER 3. DEVELOPMENT AND EVALUATION OF SEOA NS VIA WET BALL 
MILLING OPTIMIZED BY DESIGN OF EXPERIMENTS (DOE) 
3.1 INTRODUCTION 
Design of experiments (DOE) was first exploited in 1958 by Fisher (135-137), and has 
since been used extensively in various fields including agriculture engineering food science 
and pharmacy. DOE is a methodology for studying any response that varies as a function of 
one or more independent variables. By observing the response under a planned matrix of 
settings, a statistically valid mathematical model for the responses within the designed space 
can be determined (138). The use of DOE is a revolutionary approach to optimization and a 
very useful tool for the screening of experimental parameters. Simple experimental designs 
and statistical tools for data analysis can provide much information about the system under 
scrutiny with the requirement of much less number of experiments to be carried out (139). 
The experimental method of “changing one separate factor at a time” (COST) or also 
termed as studying “one variable at a time” (OVAT) is still commonly used. The aim of 
optimization does not easily lead to the real optimal set of conditions and may lead to 
different implications, depending on the starting point investigated (139). The approach also 
requires many experiments covering a range of possibilities. In contrast, the DOE approach is 
to use an essential tool for studying complex systems since it offers an organized approach 
that connects the various experiments in a rational manner, giving rise to more precise 
information that can be arrived from much fewer experiments (138).  
When DOE is used, the following issues should be carefully considered (139) and they 
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are listed as follows. 
a) Factor: Experimental variable, which can be quantitative (time, temperature, 
etc.) or qualitative (solvent, buffer, etc.) 
b) Response: Property of the system that is being measured 
c) Interaction: A state where two or more factors are dependent on each other 
d) Confounding: Effects that cannot be estimated separately 
Wet ball milling is one of the widely used top-down method to prepare of NS. 
Comparing with dry ball milling, the liquid in the wet method could help reduce and remove 
the heat generated by the strong impacts of the milling media and minimize the risk of 
chemical degradation due to heat-related instability. The use of DOE has been proven to be 
efficient in optimizing the formulation variables used in milling (140, 141).  
The aim of this study was to optimize the operational parameters for preparing SEOA 
NS by wet ball milling with the help of the Minitab software (version 15, Minitab Inc. State 
College, Pennsylvania, USA) and to study the in vivo and in vitro properties of the optimized 
products produced.  
 
3.2 MATERIALS 
OA was purchased from Nanjing Qinze Pharmaceutics Ltd. Co. (Nanjing, China). SEL 
(batch M07A001, 90 % purity) and SEP (batch M07C003, 90 % purity) were obtained from 
Compass Foods Pte. Ltd. (Singapore). Methyl thiazolyl tetrazolium (MTT) and F12 Ham 
Kaighn’s modification (F12K) medium were purchased from Sigma Aldrich Ltd. Co. (St. 
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Louis, MO, USA). A549 human non small cell lung cancer cell line (NSCLC) was purchased 
from American Type Culture Collection (Rockville, MD, USA). Fetal bovine serum (FBS) 
was purchased from Hyclone Laboratories Ltd. Co. (Logan, UT, USA). 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) was purchased from 
Applichem Ltd. Co. (Darmstadt, Germany). MilliQ water (18.2 MΩ cm at 25 °C) was 
obtained from a Millipore Direct-Q ultra-pure water system (Billerica, MA, USA) and used 
throughout the study. 
 
3.3 METHODS 
3.3.1 PREPARATION OF SEOA NS BY WET BALL MILLING  
SEOA NS formulations were prepared by the wet ball milling method using a  
laboratory scaled ball mill (S1, Retsch, Haan, Germany) (Figure 3.1) with 10 mm diameter stainless 
steel balls and the milling procedure adopted was according to the method described by the 
instrument manual. In brief, SEP and SEL were mixed with OA in a beaker at predetermined 
ratio and diluted with MilliQ water as the liquid medium to a final volume of 100 mL. The 
mixture was then poured into the stainless steel milling chamber containing stainless steel 
balls. The ball milling process was performed over 25 min followed by a 5 min break to 
allow for cooling before proceeding with milling again, repeating the cycle until completion 
of the proposed milling time. After a certain prescribed period of ball milling, the suspension 
was carefully extracted by pipettes, transferred to clean BD Falcon™ 50 mL conical tubes 
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(BD Bioscience, Mississauga, Canada), centrifuged at 13000 rpm for 10 min and filtered 





Figure 3.1 Ball mill used for wet milling (Technical specifications: 220 V, 50 Hz, 75 W. 
Container dimensions (ø) x (H): 7.5 x 6.5 cm). 
 
NS preparation was optimized with respect to milling time, rotational milling speed, 
ratio of SEP to SEL and ratio of SE (SEL and SEP) to OA with the help of the Minitab 
software by 4 factors and 2 levels factorial design analysis. Milling time was set as 1 h (low 
level) and 3 h (high level); rotational milling speed was set at 300 rpm (low level) and 600 
rpm (high level); SEL : SEP was set at 1 : 1 (low level) and 9 : 1 (high level) and SE : OA 
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was set at 1 : 1 (low level) and 10 : 1 (high level). Detailed settings for the preparation of the 
various SEOA NS are shown in Table 3.1.  
 
3.3.2 PARTICLE SIZE AND POLYDISPERSITY INDEX ANALYSIS 
Dynamic light scattering (DLS) measurements were performed using the Zetasizer 
Nano-ZS90 (Malvern Instruments, Malvern, UK) at a wavelength of 532 nm. The scattering 
angle was fixed at 90 and the temperature of the sample was maintained at 25 °C. Particle 
size and polydispersity index (PDI) determinations were carried out using diluted suspensions 
by adding 4 times of each volume with MilliQ water.  
 
3.3.3 FT-IR MEASUREMENT 
Pure OA, lyophilized SEOA-GBD NS and physical mixture of SEL and SEP at 9 : 1 
(w/w) were analyzed using a FT-IR Spectrometer (PerkinElmer Spectrum 100 Series, 
Norwalk, CT, USA). Samples were mixed with anhydrous potassium bromide (1 : 100) and 
ground in a mortar and then pressed in a hydraulic press (14 tons) to small discs. The discs 
were placed under the infrared beam and the FT-IR spectra were collected in a spectral region 






3.3.4 TRANSMISSION ELECTRON MICROSCOPY (TEM)  
The NS samples were applied onto copper grids for TEM observation. The cooper grids 
were first coated by 0.25 % Formvar film and then by carbon in a sequential order. The film 
face of the grid was applied with the NS sample and then stained with 5 % PTA. Excess 
applied liquids were carefully blotted off during each step. After drying for over 10 min 
under bench lamp, the sample was ready for examination. TEM micrographs were obtained 
using a JEOL JEM 2010 transmission electronic microscope (JEM 2010, JEOL Ltd. Co., 

















Table 3.1 Detailed settings of SEOA NS made from wet ball milling 
 
NS Milling Speed (rpm) Milling Time (h) SEL to SEP ratio SE to OA ratio 
FBC 600 1 1 : 1 (5 g, 5 g) 10 : 1 (10 g, 1 g) 
HAC 300 1 9 : 1 (9 g, 1 g) 10 : 1 (10 g, 1 g) 
EAC 300 1 1 : 1 (0.5 g, 0.5 g) 1 : 1 (1 g, 1 g) 
FBD 600 3 1 : 1 (5 g, 5 g) 10 : 1 (10 g, 1 g) 
HAD 300 3 9 : 1 (9 g, 1 g) 10 : 1 (10 g, 1 g) 
EAD 300 3 1 : 1 (0.5 g, 0.5 g) 1 : 1 (1 g, 1 g) 
EBC 600 1 1 : 1 (0.5 g, 0.5 g) 1 : 1 (1 g, 1 g) 
EBD 600 3 1 : 1 (0.5 g, 0.5 g) 1 : 1 (1 g, 1 g) 
GAC 300 1 9 : 1 (0.9 g, 0.1 g) 1 : 1 (1 g, 1 g) 
GAD 300 3 9 : 1 (0.9 g, 0.1 g) 1 : 1 (1 g, 1 g) 
GBC 600 1 9 : 1 (0.9 g, 0.1 g) 1 : 1 (1 g, 1 g) 
GBD 600 3 9 : 1 (0.9 g, 0.1 g) 1 : 1 (1 g, 1 g) 
HBC 600 1 9 : 1 (9 g, 1 g) 10 : 1 (10 g, 1 g) 
HBD 600 3 9 : 1 (9 g, 1 g) 10 : 1 (10 g, 1 g) 
FAC 300 1 1 : 1 (5 g, 5 g) 10 : 1 (10 g, 1 g) 
FAD 300 3 1 : 1 (5 g, 5 g) 10 : 1 (10 g, 1 g) 
 
The first alphabets (E, F, G, H) encode the ratio between SEL to SEP and SE to OA, the 




 3.3.5 PERCENT ENCAPSULATION EFFICIENCY (EE %) AND SATURATION 
SOLUBILITY  
EE % and OA saturation solubility of SEOA NS were measured and calculated by the 
results from HPLC analysis. HPLC analysis was carried out using an Aglient Model 1100 
HPLC unit (Agilent, Palo Alto, CA, USA) with a C18 column (ODS 5 µm, 3.9 mm x 150 
mm; Waters, Milford, MA, USA) and mobile phase of 65 % acetonitrile and 35 % MilliQ 
water. Column temperature was maintained at 24 °C. Flow rate was 1 mL/min and uv 
detection wavelength was 210 nm. Standard samples were dissolved in methanol. The freshly 
prepared NS were dissolved in at least 5 x volumes of methanol to ensure that OA was fully 
dissolved and fell within the standard calibration curve concentration range. All samples were 
filtered through 0.22 µm membranes before measurements. The calibration curve over the 
concentration range of 0.02–0.20 mg/mL was constructed by plotting the peak area of the 
analyte against the concentration spiked for each media. Six independently weighed 
concentrations (0.02, 0.04, 0.06, 0.08, 0.10, 0.20 mg/mL) were used to obtain the calibration 
curve. The linearity of the assay procedure was determined by calculation of a regression line. 
Concentrations of OA in diluted SEOA NS samples were obtained from the resulting peak 
areas and the regression equation of the calibration curve. Saturation solubility of OA was 
calculated from the amount of OA dissolved in diluted sample multiplied by the dilution 
factor. For calculation of the EE % of OA, the following equation was used, 
EE % = OANS/OAT × 100 % 
Where, OANS indicates amount of OA in NS and OAT indicates the total amount of OA 
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added during preparation. 
3.3.6 LYOPHILIZATION OF SEOA NS AND FREE OA SOLUTION 
SEOA NS and free OA solution were frozen at -80 °C overnight and then freeze dried 
(Labconco Corp., Kansas City, MO, USA) for 24 h at -70 °C and 0.02 mbar. 
 
3.3.7 IN VITRO DISSOLUTION TEST 
Dissolution experiments were carried out using a dissolution apparatus (Model 2100c; 
Distek, North Brunswick, NJ, USA) according to the USP 29 Apparatus 2 (United States 
Pharmacopeia Convention, Inc., Rockville, MD, USA, 2006). The dissolution medium was 
500 mL pH 7.4 phosphate buffer solution containing 1 % sodium dodecyl sulphate (SDS), 
thermostated at 37 ± 0.5 °C with paddles rotated at 100 rpm. SEOA-GBD NS, SEOA-GBD 
NS lyophilized powder, OA coarse suspension (suspended in N,N-DMAC : PEG400 : water 
in the ratio of 2 : 4 : 1, v/v/v) and SEOA-GBD NS in dialysis bags (MWCO 2,000; Spectrum 
Medical Industries Inc, Singapore) were all added into the dissolution media, each bag 
contained an estimated amount equivalent to 8 mg OA. Samples (3 mL) were withdrawn at 
predetermined time intervals and filtered through 0.22 μm filters. After each withdrawal, an 
equal volume of the dissolution medium was added to maintain the volume constant. The 
content of dissolved OA was determined using HPLC. All dissolution experiments were 
performed in triplicates, all sample analyses were carried out in triplicates and reported 
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results were the mean values. 
 
3.3.8 STABILITY STUDY 
The effect of storage time on the stability of SEOA NS was investigated at 4 °C. 
Physical stability was measured as the percentage changes in particle size of SEOA NS after 
storage of 15 and 30 days. Chemical stability was measured as the relative concentration 
(percentage of original concentration) of OA in NS (after filtration) at the same time intervals. 
Each sample measurement was repeated thrice, and all studies were carried out by three 
independent experiments. 
 
3.3.9 CYTOTOXICITY OF OA AND SEOA NS 
A549 human NSCLC cells were cultured in F12 Ham Kaighn’s modification (F12K) 
medium, supplemented with 10 % FBS, 10 mM HEPES, 100 U/mL penicillin G and 100 
µg/mL streptomycin. The cells were maintained at 37 °C in a 5 % CO2 humidified incubator. 
To determine cytotoxicity of OA and SEOA NS, A549 cells were seeded in 96-well plates at 
a density of 6 x 10
3
 cells per well and incubated for 24 h at 37 °C in a 5 % CO2 humidified 
incubator. Culture media were then removed and replaced with 100 µL fresh media (blank) or 
fresh media containing 0.5 % DMSO (control) or different concentrations of OA (in media 
with 0.5 % DMSO) or SEOA NS. After 24 and 72 h incubation, 10 µL MTT solution (5 
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mg/mL in PBS) was added to each well. After incubation at 37 °C for 4 h, the mixtures in the 
wells were removed, and 110 µL DMSO was added to each well and shaken at 100 rpm for 
30 min. Absorbance was measured using a multiplate reader (Molecular Devices, Sunnyvale, 
CA, USA) at 590 nm. Proliferation rate (%) was calculated as ((sample reading-blank reading) 
/ (control reading-blank reading)) × 100. 
 
3.3.10 PHARMACOKINETICS STUDY 
3.3.10.1 INTRAVENOUS AND ORAL ADMINISTRATION OF OA TO RATS 
The study design and animal handling protocol of this pharmacokinetic study were 
followed the method described in Chapter 2. Adult male Sprague–Dawley rats (250 – 300 g) 
were purchased from the Laboratory Animal Center of the National University of Singapore. 
The rats were housed under temperature (22 ± 1 °C) and relative humidity (60 – 70 %) 
controlled environment in Animal Holding Unit of the university operated at a 12-h light/dark 
cycle. The rats were given free access to food and water before surgery. On the day before 
the pharmacokinetic study, a polyethylene tube (i.d. 0.58 mm, o.d. 0.965 mm, Becton 
Dickinson, Sparks, MD, USA) was placed into the right jugular vein through surgical implant 
under anaesthesia. The intravenous (iv) drug administration and blood sample collection were 
performed through this cannula. The rats were randomly divided into four groups (n = 5 per 
group). Group I received iv administration of OA while three other groups received oral 
doses through gavage. It is known that oral absorption may be influenced by different dietary 
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regimens and the inherent bile salt solubilisation capacity in the intestine. Hence, the rats for 
oral administration (Groups IIb, IIIb and IV) were kept in fasting condition overnight prior to 
the oral gavage and during blood collection but free access to water were allowed. However, 
such restriction was not applied to the rats that received iv administration. Rats in groups IIb 
and IIIb were administered single doses of SEOA-GBD NS by oral gavage at the doses of 10 
and 20 mg/kg were given, respectively. As controls and comparators, rats in groups I and IV 
would receive either SEOA4121 NS by iv administration (2 mg/kg) or oral administration of 
coarse OA suspension in N, N-DMAC : PEG400 : water (2 : 4 : 1, v/v/v) at the dose of 20 
mg/kg. Serial blood samples (200 μL) were collected from each animal at 1, 5, 15, 30, and 45 
min, and 1, 1.5, 2, 3, 4, 6, 8, 10 and 12 h after iv administration and at 5, 15, and 30 min, and 
1, 1.5, 2, 3, 4, 6, 8, 10 and 12 h after oral administration. The cannula was flushed and blood 
was replaced by an equivalent volume of heparin–saline (20 IU/mL heparin in normal saline) 
after each draw of blood sample. Plasma samples were collected after centrifugation (3,000 g 
x 5 min) of the blood samples and stored at −80 °C until LC-ESI-MS/MS analysis. 
 
3.3.10.2 SAMPLE PREPARATION AND CALIBRATION  
The sample preparation method (liquid-liquid extraction) was adopted from a previous 
study with minor modification (131). The plasma sample (100 μL) was spiked with a 
methanol solution (5 μL) of GA (20 μg/mL) as IS and mixed briefly in a clean 2 mL 
centrifuge tube. Next, ethyl acetate (300 μL) was added to the tube and mixed for 1 min to 
facilitate extraction. After this liquid-liquid extraction step, the tube was centrifuged (13,000 
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g x 10 min) and the ethyl acetate layer was carefully transferred to another clean tube. The 
extraction procedure was repeated for two additional aliquots of ethyl acetate and the 
cumulated ethyl acetate layers were collected in the same tube. The ethyl acetate sample was 
then dried under nitrogen flow at 40 °C. The residue was reconstituted with methanol (75 μL) 
and centrifuged (13,000 g x 5 min). The supernatant was injected (10 μL) into the HPLC to 
determine OA content. Calibration standards were prepared with 100 μL blank plasma 
samples, adopting the same preparation procedure. The calibration curve was obtained using 
blank plasma samples spiked with OA and internal standard. The blank plasma samples were 
obtained from pooled rat plasma. The calibration curve for OA was linear (r
2
 = 0.9907) 
within the range of 20–2,000 ng/mL of OA. 
 
3.3.10.3 CHROMATOGRAPHY AND TANDEM MASS SPECTROMETRY 
ANALYSIS 
The concentrations of OA in plasma were determined by the same method as described 
in Chapter 2. Briefly, the HPLC system was an Agilent 1100 equipped with the G1312A 
binary pump and a G1379A degasser (Agilent, Palo Alto, CA, USA). The HPLC column was 
a C18 column (300 mm × 2. mm i.d.) packed with 3 μm ODS stationary phase (Hypersil 
Aquasil, Thermo Scientific, Waltham, MA, USA) which was protected with a guard column 
(Inertsil ODS-3; GL Sciences, Tokyo, Japan). The HPLC mobile phase consisted of 
acetonitrile/10 mM ammonium acetate buffer pH 6.5 (15 : 85, v/v). The flow rate was set at 
0.30 mL/min and analysis was performed in an isocratic mode. The mass spectrometer was 
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the Qtrap 3000 model with an electrospray ionization (ESI) interface (Applied Biosystems, 
Toronto, Canada). Negative ion ESI with the collision energy -30 V, curtain gas 10 psi and 
ion source temperature 200 °C were used. Quantification was performed with multiple 
selected reaction monitoring (MRM) mode. The transition of OA is 455.5/455.5 (m/z) and 
GA (IS) is 469.5/425.5 (m/z) with a scan time of 100 ms per transition. 
 
3.3.10.4 RESULTS ANALYSIS 
WinNonlin standard Version 5.01 (Scientific Consulting Inc., Apex, NC, USA) was 
used to analyze the pharmacokinetic parameters and a non-compartmental model was 
adopted for the analysis. The area under the plasma concentration (AUC) versus time curve 
(AUC0→t) in rats that received oral administration (Groups IIb, IIIb and IV) was calculated by 
the linear trapezoidal rule with the time point from 0 to the last detectable time point, whereas 
the AUC0→t in rats that received iv dosing (Group I) was calculated through the same rule 






. Absolute bioavailability (F %) of OA after oral administration 
(Groups 2 - 4) was calculated using the following equation: 
0 t
0 t
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  = (FA/FB) ×100 
3.3.11 STATISTICAL ANALYSIS 
Results were presented as mean ± standard deviation (Std). Statistical significance of the 
results was analyzed using two-tail independent sample t test or one-way ANOVA. Values of 
p<0.05 were considered statistically significant. Minitab software (version 15, Minitab Inc. 
State College, Pennsylvania, USA) was used to perform factorial design analysis. 
 
3.4 RESULTS AND DISCUSSIONS 
3.4.1 CHARACTER OF SEOA NS 
3.4.1.1 PARTICLE SIZE AND POLYDISPERSE INDEX (PDI) OF DIFFERENT SEOA 
NS FORMULATIONS  
The particle size and polydispersity index (PDI) of SE-OA NS were measured by the 
dynamic light scattering (DLS). Figure 3.2a shows a SEOA NS typical size normal 
distribution curve by volume (%) and the measured particle size was below 100 nm. Figure 
3.2b gives the comparison chart of all the 16 formulations studied. Table 3.2 indicates the 
detailed size data and statistical analysis by one-way ANOVA. The mean particle sizes of the 
16 formulations distributed widely, and the overall averaged size was 93.67 ± 53.53 
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(nm).With the exception of FBC (252.53 nm), FBD (156.87 nm) and HBD (146.70 nm), 
other particle sizes were all below 100 nm (see Table 3.2) and the averaged size, without the 
three NS mentioned, decreased to 72.51 ± 17.66 (nm). 
The PDI of 16 formulations also varied considerably, from the lowest at 0.21 to biggest 
value of 1.0. The overall averaged PDI was 0.53 ± 0.29, but if the five formulations with 
largest PDI (FBC, HAD, HBC, FBD, and FAD) values were excluded in the calculations, the 
averaged PDI of the rest would drop to 0.34 ± 0.08. 
The above observations had indicated that some NS formulations “impaired” the overall 
property of the 16 SEOA NS formulations that were prepared by wet ball milling. To obtain a 
better understanding of the operational mechanisms in the milling process, the influence of 
the four major preparation parameters will be elaborated later, with the help of the analysis 


















Figure 3.2a Representative particle size distribution data obtained from Zetasizer 
(Nano-ZS90) Instrument by the intensity of volume. Figure 3.2b Particle size of different 





























Table 3.2 Comparison of size and PDI  
 
NS Size (nm) PDI 
1.FBC 252.53 ±62.12
2,3,4,5,6,7,8,9,10,11,12,13,14,15,16




















  0.90 ± 0.11
2,3,7,9,10,11,12,13,14,15,16
  
6.FBD 156.87 ± 23.72
1,3,4,5,7,8,9,10,11,12,13,14,15,16
  1.00 ± 0.00
2,3,4,7,9,10,11,12,13,14,15,16
  
7.FAC 57.25 ± 18.73
1,2,6
  0.21 ± 0.05
1,2,4,5,6,8,11,12,13,14
  
8.FAD 35.83 ± 1.11
1,2,6,12
  0.96 ± 0.04
2,3,7,9,10,11,12,13,14,15,16
  
9.EAC 77.09 ± 1.93
1,2,6
  0.31 ± 0.02
1,2,4,5,6,8
  
10.EAD 79.84 ± 0.95
1,2,6
  0.33 ± 0.05
1,4,5,6,8
  
11.EBC 85.46 ± 2.08
1,2,6
  0.35 ± 0.04
1,4,5,6,7,8
  
12.EBD 99.20 ± 1.49
1,6,8
  0.44 ± 0.03
1,3,4,5,6,7,8,15
  
13.GAC 87.77 ± 1.35
1,2,6
  0.41 ± 0.02
1,3,4,5,6,7,8
  
14.GAD 68.99 ± 1.51
1,2,6
  0.35 ± 0.03
1,4,5,6,7,8
  
15.GBC 71.52 ± 1.19
1,2,6
  0.31 ± 0.01
1,2,4,5,6,8,12
  
16.GBD 65.73 ± 1.71
1,2,6




Data represent 3 independent experiments repeated in triplicate. Values are presented as 
means ± std. 
1
, significantly different compared with FBC. 
2
, significantly different compared 
with HBD. 
3
, significantly different compared with HAC. 
4
, significantly different compared 
with HAD. 
5
, significantly different compared with HBC. 
6
, significantly different compared 
with FBD. 
7
, significantly different compared with FAC. 
8
, significantly different compared 
with FAD. 
9
, significantly different compared with EAC, 
10
, significantly different compared 
with EAD. 
11
, significantly different compared with EBC, 
12
, significantly different compared 
with EBD.
13
, significantly different compared with GAC, 
14
, significantly different compared 
with GAD. 
15
, significantly different compared with GBC. 
16
, significantly different compared 









3.4.1.2 MORPHOLOGY OF MILLED NS DETERMINED BY TEM 
Determination of the morphology and particle size of SEOA NS were carried out by 
imaging using the transmission electron microscopic (TEM). Figure 3.3 shows the 
representative TEM photomicrographs of SEOA NS prepared by wet ball milling. In Figure 
3.3a, with the magnification of 15,000 times, the particles of NS can be found scattering 
widely on the cooper grid (the small black dots). In Figure 3.3b, the particles of SEOA NS 
can be observed clearer with a magnification of 40,000 times. The NS particles were 
generally spherical in shape and with a mean diameter of around 20 nm. The smaller particle 
sizes observed as compared to the result of DLS may be attributed to the nano-aggregation 
effect in free liquid media of the high energy free NS particles. Free single particles of NS 
tended to aggregate together and DLS method could only provide sizes by the overall 
Brownian effect of the aggregates, thus only giving the aggregates’ size distribution. The less 
opaque outer shells of each separate particle were likely to be constituted layers of the 
surfactants, SEL and / or SEP. The surfactant layers around the NS particles were most likely 
important to the formation of NS as they were believed to act as barriers preventing 
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Figure 3.3 Representative TEM of SEOA NS produced by wet ball milling method. In 
Figure 3.3a, bar = 200 nm, magnification 15,000 times. In Figure 3.3b, bar = 100 nm, 
magnification 40,000 times. 
 
 
3.4.1.3 SEOA NS ENCAPSULATION EFFICIENCY (EE %) AND SATURATION 
SOLUBILITY 
Saturation solubility and EE % results are shown in Figure 3.4 and Table 3.3. The 
saturation solubility of OA obtained ranged from 2.08 to 5.49 mg/mL, which were much 
higher than free OA, and also higher than the previously reported SEOA NS prepared using 
the emulsion solvent evaporation method. Of all the formulations studied, HBD (5.49 mg/mL, 
54.88 %) and FAD (5.36 mg/mL, 53.63 %) had the highest results. A further study on the 






The FT-IR measurement was carried out to verify the existence of possible structure 
interactions between surfactants and OA. Figure 3.5 shows that all major peaks of free OA 
were still present in the lyophilized SEOA NS. This observation indicated that OA was not 
























   
Figure 3.4 OA saturation solubility in SEOA NS. Data is presented as mean (mg/mL) ± 





































Table 3.3 Comparison of OA saturation solubility and EE % 
 
NS Saturation Solubility (mg/mL) EE % 
1.FBC 4.10 ± 0.13
3,4,5,6,7,8,9,10,11,12,13,14,15,16
  41.03 ± 1.26
3,4,5,6,7,8,9,10,11,12,13,14,15,16
  
2.HAC 4.25 ± 0.14
3,5,6,7,8,9,10,11,12,13,14,15,16
  42.49 ± 1.45
3,5,6,7,8,9,10,11,12,13,14,15,16
  
3.EAC 2.08 ± 0.00
1,2,4,5,6,7,8,10,11,12,13,14,15,16
  20.82 ± 0.04
1,2,4,5,6,7,8,10,11,12,13,14,15,16
  
4.FBD 4.58 ± 0.04
1,3,5,6,7,8,9, 10,11,12,13,14,15,16
  45.79 ± 0.43
1,3,5,6,7,8,9, 10,11,12,13,14,15,16
  
5.HAD 5.36 ± 0.12
1,2,3,4, 6,7,8,9, 10,11,12
  53.63 ± 1.17
1,2,3,4, 6,7,8,9, 10,11,12
  
6.EAD 2.77 ± 0.05
1,2,3,4,5,9,13,14,15,16
  27.70 ± 0.54
1,2,3,4,5,9,13,14,15,16
  
7.EBC 2.55 ± 0.08
1,2,3,4,5,,8,12,13,14,15,16
  25.51 ± 0.77
1,2,3,4,5,,8,12,13,14,15,16
  
8.EBD 3.15 ± 0.07
1,2,3,4,5,7,9,11,13,14,15,16
  31.51 ± 0.71
1,2,3,4,5,7,9,11,13,14,15,16
  
9.GAC 2.22 ± 0.29
1,2,4,5,6,8,10,11,12,13,14,15,16





  28.11 ± 2.79
1,2,3,4,5,9,13,14,15,16
   
11.GBC 2.68 ± 0.06
1,2,3,4,5,8,9,13,14,15,16
  26.83 ± 0.60
1,2,3,4,5,8,9,13,14,15,16
   
12.GBD 3.11 ± 0.10
1,2,3,4,5,7,9, 13,14,15,16
  31.08 ± 0.96
1,2,3,4,5,7,9, 13,14,15,16
   
13.HBC 5.04 ± 0.03
1,2,3,4,6,7,8,9,10,11,12,14
  50.41 ± 0.34
1,2,3,4,6,7,8,9,10,11,12,14
  
14.HBD 5.49 ± 0.16
1,2,3,4,6,7,8,9,10,11,12,13,15
  54.88 ± 1.64
1,2,3,4,6,7,8,9,10,11,12,13,15
  
15.FAC 5.03 ± 0.11
1,2,3,4,6,7,8,9,10,11,12,14
  50.35 ± 1.08
1,2,3,4,6,7,8,9,10,11,12,14
  
16.FAD 5.36 ± 0.23
1,2,3,4,6,7,8,9,10,11,12




Data represent 3 independent experiments repeated in triplicate. Values are presented as 
means ± std. 
1
, significantly different compared with FBC. 
2
, significantly different compared 
with HAC. 
3
, significantly different compared with EAC. 
4
, significantly different compared 
with FBD. 
5
, significantly different compared with HAD. 
6
, significantly different compared 
with EAD. 
7
, significantly different compared with EBC. 
8
, significantly different compared 
with EBD. 
9
, significantly different compared with GAC, 
10
, significantly different compared 
with GAD. 
11
, significantly different compared with GBC, 
12
, significantly different compared 
with GBD.
13
, significantly different compared with HBC, 
14
, significantly different compared 
with HBD. 
15
, significantly different compared with FAC. 
16
, significantly different compared 








Figure 3.5 FTIR spectra of lyophilized SEOA-GBD NS (A), free OA (B) and physical 













3.4.1.5 STABILITY OF SEOA NS 
Physical stability of SEOA NS can be elucidated from the data shown in Table 3.4. 
Although the initial particle size was very small upon manufacture, most of the particles 
tended to aggregate together with time and grow to much larger entities after prolonged 
storage. After storage for 15 days, size change found ranged from 15.9 % to 3510.6 % and 30 
days storage produced growth ranged from 37.4 % to 4467.4 %. Among the products 
prepared, GBD (23.5 % for 15 days, and 37.4 % for 30 days) and GAD (15.9 % for 15 days, 
and 47.0 % for 30 days) were the more stable SEOA NS products. 
Table 3.5 demonstrates the chemical stability of SEOA NS. During the first 15 days 
storage, most of the NS products were relatively stable (>80 % relative concentration). The 
chemical stability after 30 days storage varied from 68.7 % to 93.7 %. GBD (103.5 % for 15 





















Table 3.4 Physical stability of SEOA NS 
 
Data represent 3 independent experiments repeated in triplicate. Original particle sizes of NS 
were set as 100. Values are presented as means ± std. 
1
, significantly different compared with 
FBC. 
2
, significantly different compared with HBD. 
3
, significantly different compared with 
HAC. 
4
, significantly different compared with HAD. 
5
, significantly different compared with 
HBC. 
6
, significantly different compared with FBD. 
7
, significantly different compared with 
FAC. 
8
, significantly different compared with FAD. 
9
, significantly different compared with 
EAC, 
10
, significantly different compared with EAD. 
11
, significantly different compared with 
EBC, 
12
, significantly different compared with EBD.
13
, significantly different compared with 
GAC, 
14
, significantly different compared with GAD. 
15
, significantly different compared 
with GBC. 
16
, significantly different compared with GBD (p<0.05). Statistics were carried 
out by one- way ANOVA. 
 
 
NS 15-day size change (%) 30-day size change (%) 
1 FBC 
1230.91 ± 774.40 
2,3,7,9.10,11,12,13,14,15,16
  
1405.94 ± 400.95 
2,3,7,9,10,11,12,13,14,15,16
  
2 HBD 227.65 ± 36.78 
1,3,4,6,7,8
  272.71 ± 212.84 
1,3,4,6,7,8 
3 HAC 
3510.55 ± 1017.02 
1,2,4,5,6,7,8,9,10,11,12,13,14,15,16
  








1989.83 ± 768.56 
2,3,7,9, 10,11,12,13,14,15,16 
5 HBC 532.32 ± 182.68
 3,7,8
















4467.42 ± 1481.09 






1882.04 ± 571.84 
2,3,7, 9, 10,11,12,13,14,15,16
  
9 EAC 127.13 ± 6.48
 1,3,4,6,7,8
  245.30 ± 5.15 
1,3,4,5,6,7,8
  
10 EAD 97.09 ± 5.97 
1,3,4,6,7,8
  101.85 ± 3.10 
1,3,4,5,6,7,8
 
11 EBC 45.92 ± 1.88 
1,3,4,6,7,8
  140.82 ± 8.61 
1,3,4,5,6,7,8
 
12 EBD 27.58 ± 2.37 
1,3,4,6,7,8
 126.64 ± 12.93 
1,3,4,5,6,7,8
  
13 GAC 37.32 ±2.75 
1,3,4,6,7,8
 79.82 ± 12.82 
1,3,4,5,6,7,8
 
14 GAD 15.87 ± 2.96 
1,3,4,6,7,8
 46.98 ± 7.90 
1,3,4,5,6,7,8
 
15 GBC 31.16 ± 3.55 
1,3,4,6,7,8
 105.81 ± 11.42 
1,3,4,5,6,7,8
 
16 GBD 23.45 ± 2.04 
1,3,4,6,7,8





Table 3.5 Chemical stability of SEOA NS 
 
NS 15-day relative concentration (%) 30-day relative concentration (%) 
1 FBC 99.66 ± 0.74 
4,5,7,8,13
  84.78 ± 2.92
4,5,8,14
  





3 EAC 101.55 ± 4.26
 2,4,5,6,7,8,13
  87.23 ± 2.14
4,5,8,14
  
4 FBD 83.35 ± 1.68 
1,3,9,10,11,12
  74.79 ± 5.29
1,3,9,10,12,16
  
5 HAD 83.46 ± 6.83 
1,3,9,10,11,12
  68.68 ± 4.96
1,2,3,6,7,9,10,11,12,13,15,16
  
6 EAD 87.01 ± 8.10 
3,9,11,12
  80.81 ± 6.89
5,12,14
  
7 EBC 80.71 ± 0.44
 1,3,9,10,11,12
  79.95 ± 9.05
5,9,12
  
8 EBD 80.01 ± 1.07
 1,3,9,10,11,12
  75.73 ± 5.06
1,3,9,10,12,16
  
9 GAC 107.24 ± 11.86 
2,4,5,6,7,8,13,14,15,16
  88.98 ± 1.58
4,5,7,8,13,14
  





11 GBC 101.87 ± 18.30 
2,4,5,6,7,8,13
  82.89 ± 0.34 
5,12,14
  
12 GBD 103.50 ± 9.74 
2,4,5,6,7,8,13,15
 93.68 ± 3.70 
2,4,5,6,7,8,11,13,14,15
  
13 HBC 84.98 ± 5.37 
1,3,9,10,11,12 
78.43 ± 11.69 
5,9,12
  
14 HBD 91.09 ± 5.43
 9
  71.12 ± 0.70
1,2,3,6,9,10,11,12,15,16
  
15 FAC 89.36 ± 6.92 
9,12
  81.42 ± 6.39
5,12,14
  
16 FAD 91.52 ± 6.56 
9




Data represent 3 independent experiments repeated in triplicate. Original OA concentrations 
in NS were set as 100. Values are presented as means ± std. 
1
, significantly different 
compared with FBC. 
2
, significantly different compared with HAC. 
3
, significantly different 
compared with EAC. 
4
, significantly different compared with FBD. 
5
, significantly different 
compared with HAD. 
6
, significantly different compared with EAD. 
7
, significantly different 
compared with EBC. 
8
, significantly different compared with EBD. 
9
, significantly different 
compared with GAC, 
10
, significantly different compared with GAD. 
11
, significantly 
different compared with GBC, 
12
, significantly different compared with GBD.
13
, significantly 
different compared with HBC, 
14
, significantly different compared with HBD. 
15
, significantly 
different compared with FAC. 
16
, significantly different compared with FAD (p<0.05). 





3.4.1.6 ANALYSIS OF THE INFLUENCE OF PROCESS VARIABLES ON NS 
PROPERTIES 
3.4.1.6.1. ANALYSIS OF PARTICLE SIZE INFLUENCING FACTORS 
To find out how the four main production parameters (milling speed, milling time, SEL : 
SEP ratio and SE : OA ratio) influenced the particle size of SEOA NS, a factorial design was 
planned and results analysed by the use of the Minitab software (version 15, Minitab Inc. 
State College, Pennsylvania, USA). 
From Figures 3.6a and b, most of the main parameters and their interactions had 
significant relationship with the resultant particle size (p<0.05) but not including milling time 
and its interactions (the standardized effect value below 2.04, p>0.05, Figure 3.6b). To 
further analysis the main effects, the three main parameters with significant effects were 
compared together (Figure 3.6c). Among them, RPM (milling speed) had the steepest slope, 
which meant that it had the largest impact. Relatively slower milling speed tended to yield 
smaller particle size NS. This finding may be attributed to the high milling speed which had 
produced more heat-related effects due to impact energy generated during ball milling 
preparation process. The NS products were hence more likely aggregated together, to form 
larger entities and hence reduced the surface free energy. Higher SEL to SEP ratio led to 
smaller particle size products and this was due to better stabilization effects of surfactant ratio. 
Lower SE : OA ratio produced lower drug encapsulation by surfactants and hence, also 
smaller particle sized products.   
Interactive effect analysis was carried out to study the interactions between the three 
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main factors and findings are shown in Figures 3.6d1, d2 and d3. From Figure 3.6d1, in the 
study on the relationship between milling speed and SE : OA ratio, a lower milling speed 
(300 rpm) and higher SE : OA ratio (10 : 1) produced NS with smaller particle sizes. With a 
higher milling speed (600 rpm) and higher SE : OA ratio (10 : 1), the NS products were 
found to be of bigger particle size.  
Figure 3.6d2 illustrates the correlation between SE : OA and SEL : SEP ratio. It was 
shown that with a lower SE : OA ratio (1 : 1) and bigger SEL : SEP ratio (9 : 1), the product’s 
particle size was smaller. On the contrary, bigger particles were produced with a higher SE : 
OA ratio (10 : 1) and smaller SEL : SEP ratio (1 : 1).  
In Figure 3.6d3, the relationship between milling speed and SEL : SEP ratio showed that 
smaller particles were produced when a lower milling speed (300 rpm) and smaller SEL : 
SEP ratio (1 : 1) were used whilst bigger sized products were produced by higher milling 





















































Normal Probability Plot of the Standardized Effects






















Pareto Chart of the Standardized Effects
















































Figure 3.6 Minitab analysis of Particle Size influence factors. Normal Probability Plot of 
the Standardized Effects (3.6a), Pareto Chart of the Standardized Effects (3.6b), Main 
Effects Plot (data means) for Particle Sizes (3.6c), Interaction Plot (data means) for 
Particle sizes between milling speed and SE : OA (3.6d1),. Interaction Plot (data means) 
for Particle sizes between SE : OA and SEL : SEP (3.6d2), and Interaction Plot (data 





























Interaction Plot (data means) for Particle Size
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3.4.1.6.2. ANALYSIS THE FACTORS INFLUENCING THE PDI OF NS PRODUCTS 
The four main production parameters (milling speed, milling time, SEL : SEP ratio and 
SE : OA ratio) were studied for their impact on the PDI of SEOA NS by the use of a factorial 
design. 
From Figures 3.7a and b, all of the four parameters and their interactions had significant 
relationship with the PDI value (p<0.05) and SE : OA ratio had the highest effects (Figure 
3.7b). For further analysis of the main effects, the four main production parameters were 
compared with one another (Figure 3.7c). Amongst the parameters, SE : OA ratio was found 
to possess the largest slope, which meant that it had the strongest influencing effect. 
Although higher SE : OA ratio showed higher drug encapsulation efficiency and higher 
saturation solubility, it was also found to be associated with resulting in larger particle sizes 
(Figure 3.6c) and wider PDI distributions and may had implied reduced stability of the 
production process. Faster milling speed and longer milling time had resulted in 
encapsulating more drug with the higher energy and heat input but the PDI became broader. 
It was evident that with higher SEL : SEP ratio, the particle size (Figure 3.6c) and PDI were 
both lower, suggesting that a high SEL : SEP ratio value had a close relationship with the 
optimized structure of SEOA NS produced and conferred better product stability.    
Interaction effects analysis was carried out to study possible interactions between SE : 
OA ratio and the three other factors (Figures 3.7d1, d2 and d3). From Figure 3.7d1, the 
relationship between milling time and SE : OA ratio shows that with higher SE : OA ratio 
(10 : 1) and longer milling time (3 h), the prepared NS had a larger PDI. With a lower SE : 
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OA ratio (1 : 1) and shorter milling time (1 h), the distribution was relatively smaller.  
Figure 3.7d2 illustrates the correlation between SE : OA and milling speed. It was found 
that with smaller SE : OA ratio (1 : 1), irrespective of the milling speed being slow (300 rpm) 
or fast (600 rpm), the particle size distributions were narrower. On the contrary, broader 
particle size distribution was observed with the use of higher SE : OA ratio (10 : 1) at a high 
milling speed (600 rpm).  
Figure 3.7d3 shows the relationship between SE : OA ratio and SEL : SEP ratio and it is 
noted that when SE : OA was low (l : 1), regardless of the rations of SEL : SEP, low (1 : 1) or 
high (9 : 1), the PDI remained small. Large PDI values were produced by a low SEL : SEP 








































































Normal Probability Plot of the Standardized Effects






















Pareto Chart of the Standardized Effects
















































Figure 3.7 Minitab analysis of PDI influence factors. Normal Probability Plot of the 
Standardized Effects (3.7a), Pareto Chart of the Standardized Effects (3.7b), Main 
Effects Plot (data means) for PDI (3.7c), Interaction Plot (data means) for PDI between 
milling time and SE : OA (3.7d1),. Interaction Plot (data means) for PDI between SE : 
OA and milling speed (3.7d2), and Interaction Plot (data means) for PDI between SE : 


























Interaction Plot (data means) for PDI 
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3.4.1.6.3 ANALYSIS OF THE SATURATION SOLUBILITY INFLUENCING 
FACTORS 
As the initial total amount of OA used was same (1 g) for all formulations studied, the 
EE % value could be relevant as a determinant parameter to reflect saturation solubility. The 
examination of how the four production parameters had influenced the final OA saturation 
solubility in SEOA NS and the results of the factorial design analysis were critically 
examined. 
From Figures 3.8a and b, most of the production parameters (including SE : OA ratio, 
milling time, interaction between milling speed and SEL to SEP ratio) are shown to have 
significant relationships with the saturation solubility (p<0.05). To further analysis this 
relationship, the four main production parameters were compared together (Figure 3.8c). 
Among the parameters, milling time and SE to OA ratio showed steeper slopes, which meant 
their higher influences. The two factors were selected for further interactive effect analysis 
(Figures 3.8d and e). The results showed that SE : OA ratio had a stronger influence on 
saturation solubility than time (a steeper slope) and hence, it was considered as the most 
important factor associated with saturation solubility. A possible reason for this was that the 
presence of a higher concentration of surfactant could have brought about better 
encapsulation, and more drugs were encapsulated. Prolonging the milling time was also seen 
to help to encapsulate more drugs. The interaction effect shown in Figure 3.8e indicates that 
with a high SE : OA ratio (10:1) and 3 h milling improved the yield SEOA NS by generating 













































Normal Probability Plot of the Standardized Effects






















Pareto Chart of the Standardized Effects














































Figure 3.8 Minitab analysis of Saturation Solubility influence factors. Normal 
Probability Plot of the Standardized Effects (3.8a), Pareto Chart of the Standardized 
Effects (3.8b), Main Effects Plot (data means) for Saturation Solubility(four parameters) 
(3.8c), Main Effects Plot (data means) for Saturation Solubility (two major parameters) 































Interaction Plot (data means) for Saturation Solubility 
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3.4.1.6.4 ANALYSIS OF PHYSICAL STABILITY INFLUENCING FACTORS 
The effects of the four production parameters influencing the physical stability of SEOA 
NS were studied by the determination of the differences between the groups through a 
factorial design analysis on percent particle size change after 30 days of storage. 
From Figures 3.9a and b, the main production parameters, SE : OA ratio, milling speed, 
interaction between milling speed and SE : OA ratio, and their interactions are shown to have 
significant relationships with the resultant physical stability (p<0.05) but not SEL : SEP ratio 
(the standardized effect value below 2.04, p>0.05, Figure 3.9 b). To further study the main 
effects of influence, the three production parameters with significant effects were compared 
together (Figure 3.9c). Among them, SE : OA ratio showed the steepest slope, which meant 
that it had the largest influence effect. Relatively higher SE : OA ratio yielded higher 
saturation solubility, EE % (discussed in Section 3.4.1.6.3) and hence, higher concentration 





[C( ) V D / RT]
dt 9
     , Ostwald ripening rate ω (indicating as change rate of 
particle size) correlates with the saturation solubility C(∞) and interfacial tension γ. More SE 
could reduce interfacial tension γ and hence slow down the Ostwald ripening process 
(reducing ripening rate ω). However, it can also increase solubility of OA, which enhance 
saturation solubility C (∞) and could fasten the Ostwald ripening process (increasing ripening 
rate ω). If too much SE were used, the fast Ostwald ripening process derived from increased 
saturation solubility may override the slow down effect and may result in worse physical 
stability. Longer milling time (3 h) and higher milling speed (600 rpm) may had also helped 
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to reduce the percent size change and improved the physical stability of NS produced.  
Interaction effects analysis was carried out to study the interactive relationships between 
the production three parameters (Figures 3.9d1, d2 and d3). From Figure 3.9d1, the 
relationship between milling time and SE : OA ratio shows that with a lower SE : OA ratio 
(1 : 1), immaterial if the milling time was long (3h) or short (1 h), the percent size change had 
always remained smaller (i.e. physically more stable). On the other hand, the higher percent 
size change (less stable) was produced by formulations with a higher SE : OA ratio (10 : 1) 
with a shorter milling time (1 h). 
Figure 3.9d2 illustrates the relationship between SE : OA ratio and milling speed (RPM). 
It was found that with a smaller SE : OA ratio (1 : 1), regardless whether the milling speed 
was faster (300 rpm) or slower (600 rpm), the percent size change after 30 days was smaller. 
Thus, less physically stable NS particles were produced with higher SE : OA ratio (10 : 1) 
and slower milling speed (300 rpm). 
The relationship between milling time and milling speed was studied. More stable 
SEOA NS were produced by the use of a faster milling speed (600 rpm) and a longer milling 
time (3 h). The shorter milling time (1 h) and with a slower milling speed often yielded less 













































Normal Probability Plot of the Standardized Effects






















Pareto Chart of the Standardized Effects



















































Figure 3.9 Minitab analysis of Physical Stability influence factors. Normal Probability 
Plot of the Standardized Effects (3.9a), Pareto Chart of the Standardized Effects (3.9b), 
Main Effects Plot (data means) for 30-day size change (3.9c), Interaction Plot (data 
means) for 30-day size change between milling time and SE : OA (3.9d1),. Interaction 
Plot (data means) between SE : OA and milling speed (3.9d2), and Interaction Plot (data 

























Interaction Plot (data means) for 30-day size change 
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3.4.1.6.5 ANALYSIS OF CHEMICAL STABILITY INFLUENCING FACTORS 
The four main production parameters influencing the chemical stability of SEOA NS 
were studied comparatively by the use of a factorial design on relative concentration change 
after 30 days of product storage after manufacture. 
From Figures 3.10a and b, the main production parameters (SE : OA ratio, milling time) 
and their interactions showed significant relationships to the resultant chemical stability 
(p<0.05). However, other product parameters such as milling speed and SEL : SEP ratio 
showed much less influence, the standardized effect value was found to be below 2.037, 
p>0.05 (Figure 3.10b). The two main production parameters with significant effects were 
compared together (Figure 3.10c). Between them, SE : OA ratio showed a steeper slope, 
suggesting more a marked influence effect. Lower SE : OA ratio (1 : 1) led to higher 
chemical stability. Relatively higher SE : OA ratio increased the solubilised OA in SEOA NS, 
but if the solubility increased too high and beyond the surfactants’ stabilization ability, lower 
product stability was encountered. The tendencies seen were rather similar to those observed 
for physical stability, as discussed earlier. Shorter milling time (1 h) produced better chemical 
stability since the lower energy input energy was less detrimental to the constituents present. 
Interaction effects analysis was carried out to study the interactionships between these two 
parameters (Figure 3.10d1). From Figure 3.10b, the interaction between SEL : SEP and SE : 
OA ratios were found to be the highest standardized effect and above others. This observation 
will be discussed later when explaining the findings shown in Figure 3.10d2.     
From Figure 3.10d1 showing the relationship between milling time and SE : OA ratio, it 
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can be seen that with a lower SE : OA ratio (1 : 1) and shorter milling time (1 h) produced 
SEOA NS that was more chemically stable. Differences between a longer milling time (3 h) 
and shorter milling time (1 h) were found to be rather small. In addition, with a higher SE : 
OA ratio (10 : 1) and a longer milling time (3 h), the SEOA NS prepared tended to be less 
chemically stable. 
Figure 3.10d2 illustrates the relationship between SE : OA ratio and SEL : SEP. It was 
found that a higher SEL : SEP ratio (9 : 1) and smaller SE : OA ratio (1 : 1) had caused the 
relative concentration of SEOA NS (i.e. chemical stability) after 30 days to be higher. Lower 
chemically stable particles were produced at a higher SE : OA ratio (10 : 1) and higher SEL : 
SEP ratio (9 : 1). 
From the findings and discussion above, the production parameter, SE : OA ratio had 
consistently found to play an important role when considering all the four major production 
parameters in the production of SEOA NS. The optimal SE : OA ratio of 1 : 1 yielded smaller 
particle sizes and higher physical and chemical stability. Although the higher SE : OA ratio 
of 10 : 1 brought about higher saturation solubility and EE %, the overall stability would be 
sacrificed and hence not desirable for further studies. Among all the formulations to prepare 
NS with SE : OA ratio of 1 : 1, SEOA-GBD NS (600 rpm, 3 h, SEL : SEP at 9 : 1, w/w; SE : 
OA at 1 : 1, w/w) was found to be the optimal formulation as it had the highest stability, 
relatively high saturation solubility of OA (3.11 mg/mL) and small particle size with 
relatively low PDI (65.73 nm and 0.34).Further confirmation of the assumption was made by 
viewing the response optimization results derived from the factorial design study (Figure 
3.11). Three production parameters were investigated by setting them for minimum outcomes. 
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The upper limits of 30-day particle size change (%), PDI and particle size were set at 100, 0.5, 
and 100 respectively. Saturation solubility and 30-day relative concentration (%) 
(representing chemical stability) were sought for maximum outcomes. Their lower limits 
were set as 1 and 80 respectively. After response optimization, SE-OA-GBD NS was found 
to be at the optimal formulation conditions and it was hence selected for further in vitro and 






















































Normal Probability Plot of the Standardized Effects






















Pareto Chart of the Standardized Effects









































Figure 3.10 Minitab analysis of 30-day chemical stability influence factors. Normal 
Probability Plot of the Standardized Effects (3.10a), Pareto Chart of the Standardized 
Effects (3.10b), Main Effects Plot (data means) for 30-day relative concentration (3.10c), 
Interaction Plot (data means) for 30-day relative concentration between milling time and 



























Figure 3.11 Response optimization of 30-day physical stability, PDI, particle size, 















































[600.0] [3.0] [9.0] [1.0]
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3.4.2 IN VITRO DISSOLUTION 
The influence of SEOA NS on the dissolution rate of OA was investigated by the in 
vitro dissolution profiles of OA NS with coarse OA suspension as control (Figure 3.12). The 
dissolution rate of OA coarse suspension (suspended in N, N-DMAC : PEG400: water at 2 : 
4 :1, v/v/v) was very low, only about 15 % of the drug dissolved after 120 min. On the 
contrary, the SEOA-GBD NS either in suspension form or as a lyophilized powder both 
showed a marked increase in the dissolution rate for OA as compared with the coarse OA 
suspension and 100 % of OA dissolution was achieved within 20 min.  
The dissolution rate determined by dialysis bag method was also carried out to confirm 
the fast dissolution of OA from SEOA-GBD NS as free molecular form (can pass through 
dialysis bag) or in NS form (cannot pass dialysis bag). From Figure 3.12b, by dialysis bag 
method, no OA was detected even after 60 min in the dissolution medium and the dissolution 
rate increased very slowly thereafter with the percent of dissolved OA after 120 min not even 
reaching 5 % and was less than 10 % until after 1200 min dissolution time. The findings 
collectively had suggested that most of the fast dissolving OA measured during in vitro 














Figure 3.12 Dissolution profiles of OA coarse suspension (▲) (suspended in N,N-DMAC : 
PEG400 : Water at 2 : 4 : 1, v/v/v), SEOA-GBD NS (▵) and SEOA-GBD NS lyophilized 
powder(▴) (3.12a) and SEOA GBD NS in dialysis bag (▲) (3.12b) in pH 7.4 phosphate 








































3.4.3 CYTOTOXICITY OF SEOA NS  
In NS form, the saturation solubility of OA was increased from 3.43 µg/mL (free OA) to 
3110 µg/mL (SEOA-GBD NS). Owing to the increase in OA saturation solubility, the in vitro 
cytotoxicity to A549 cell lines measured by MTT assay was also observed to have increased. 
As shown in Figure 3.13, formulation of SE OA NS significantly increased the cytotoxicity 
of OA in both time- and dose-dependent manner (also see data in Table 3.6). The 72 h IC50 
dropped from 120 µM of free OA to 45 µM and 24 h IC50 dropped from 130 µM of free OA 
to 78 µM. Although free OA is not considered potent in anti-lung cancer cells, formulated 
OA as NS form showed enhanced bioefficacy without any chemical modification. Thus, the 
usefulness of the natural derived hydrophobic compound can be changed by its physical 
transformation, to a NS form.  
 The enhanced anti-cancer effect is most likely due to the increased saturation solubility 
of OA rather than the surface-active effect of the sucrose-ester molecules. From the results 
discussed in Chapter 2 (Table 2.4), the control SE NS with SEL : SEP ratio of 9 : 1 (similar 
constituents as SEOA-GBD NS) had the 24 h IC50 of 249.10 µg/mL and 72 h IC50 of 212.60 











Figure 3.13 Dose- and time-dependent growth inhibition of A549 cells by Free OA 
dissolved in media containing 0.05 %DMSO, and SEOA-GBD NS.X axis shows OA 
concentration (µg/mL) and Y shows the percentages of viable A549 cells normalized to 
that of control (%).  
 
*, p<0.05 between SEOA-GBD 24 h and free OA 24 h; #, p<0.05 between SEOA-GBD 72h 
and free OA 72 h. Data is presented as mean (µg/mL) ± std from three independent 












Table 3.6 IC50 comparison of SEOA-GBD NS and free OA 
 
IC50 values were calculated by nonlinear regression (curve fit) of cytotoxicity data in graphs 
6a-d using sigmoidal dose response (variable slope) equation, Graphpad Prism software 












Group 24 h (µg/mL) 72 h (µg/mL) 
Free OA 59.70 ± 1.01 (130.00 µM ) 56.80 ± 1.02 (120.00 µM ) 
SEOA-GBD NS 36.53 ± 1.06 (78.00 µM ) 21.14 ± 1.06 (45.00 µM ) 
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3.4.4 SEOA NS PHARMACOKINETICS PROFILE 
3.4.4.1 PHARMACOKINETICS RESULTS AFTER INTRAVENOUS 
ADMINISTRATION 
Figure 3.14a shows the pharmacokinetics results of OA following a single iv bolus dose 
(2 mg/kg) of NS (Group I). It demonstrated that the plasma concentration of OA declined 
rapidly over the first hour of tissue distribution and was followed by a slower drop from the 
second hour onwards in the elimination profile. The maximum plasma concentration (Cmax) 
was high (21.98 ± 5.79 μg /mL) and plasma elimination half-life (T1/2) was found to be 88.41 
± 16.15 min. AUC and Cl values were calculated as 121.49 ± 27.37 μg.min/mL and 17.11 ± 
3.67 mL/min/kg, respectively. 
 
3.4.4.2 PHARMACOKINETICS RESULTS AFTER ORAL ADMINISTRATION 
The plasma pharmacokinetic profiles and the pharmacokinetic parameters following 
single oral doses of SEOA NS (10 and 20 mg/kg) and dose of coarse OA (20 mg/kg) 
suspensions are shown in Figure 3.14b and Table 3.7. In all cases, OA in NS groups resulted 
in a significantly (p<0.05) higher Cmax than the suspension formulations. However, there 
were no significant differences (p>0.05) in Tmax and T1/2. The NS group (Groups IIb and IIIb) 
had a significantly higher bioavailability (F %) values (7.71 and 7.63 over 0.56) than the 
coarse OA suspension group (Group IV) (p<0.05), while between 10 mg/kg and 20 mg/kg 
NS groups, there was no statistically significant differences (p>0.05). The rF % values of 
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Group IIb to Group IV and Group IIIb to Group IV are 13.77 and 13.63 respectively. These 
findings indicated that the SEOA-GBD NS had enhanced the oral bioavailability when 
compared with coarse OA suspension.  
The longer T1/2, although without statistical significance, exhibited by the coarse 
suspension formulation probably had indicated the sustained absorption of OA through the 
GI tract. This was possibly due to the slower dissolution of OA in the GI fluids from the 






















Figure 3.14 Mean plasma concentration-time profiles comparison of OA in rats after (a) 
IV injection at 2 mg/kg (■,n=5), (b) oral administration of OA NS at 10(▲, n=5),20 (■, 
n=5) mg/kg doses and oral administration of OA coarse suspension (▼, n=5, control) at 




























































Table 3.7 Oral pharmacokinetics profiles of SEOA NS and coarse suspension 
 
Parameter Group IIb Group IIIb Group IV 
Formulation NS NS Suspension 
Dose (mg/kg) 10.00 20.00 20.00 
AUC (μg.min/mL) 65.57 ± 18.62 a, c 129.86 ± 65.98 a, b 6.70 ±3.40 b, c 
Tmax (min) 18.00 ± 6.71 21.00 ± 8.22 13.00 ± 4.50 
Cmax (ng/mL) 1101.60 ± 250.84 
a, c 
1896.00 ± 436.38 
a, b
 70.00 ± 42.70
 b,c 
T1/2 (min) 68.00 ± 53.96 65.42 ± 15.25 102.10 ± 16.56
 




Data is presented as Mean ± Std, N=5. 
a
, p<0.05 between Groups IIb and IIIb; 
b
, p<0.05 between IIIb and IV; 
c
, p<0.05 between 2 















SEOA NS was prepared by the wet ball milling, a top-down method and critically 
evaluated. The SE : OA ratio, SEL : SEP ratio, milling time and milling speed had their 
influences on the characteristics of SEOA NS produced. The preparation of the SEAOA SE 
by a DOE method and analysed by the statistical software enabled the critical evaluation of 
the formulation parameters and the optimized product could be identified together with the 
ideal parameters for preparation. The mean particle sizes of most SEOA NS prepared were 
less than 100 nm. Except for some variations, the PDI of most formulations were found to be 
relatively low. The NS particles were generally spherical in shape and observed to be covered 
by distinct diffuse coating, possibly of the surfactant, SE, on the periphery of particles or 
their aggregates. Preparation of OA as NS by wet ball milling increased its saturation 
solubility considerably, ranging from 2.08 to 5.49 mg/mL. SEOA-GBD NS was the 
optimized formulation. SEOA-GBD NS increased the OA dissolution rate markedly. Most of 
the dissolved OA existed in the NS in solution and not dissolved as the free molecular form. 
Formulation of OA as NS significantly and substantially increased the cytotoxicity of OA. It 
reduced the proliferation rate of A549 cell lines to a much greater extent than control OA at a 
time- and dose-dependent manner. This increased activity was attributed to the nanonized 
drug and not the SE. NS of OA not only increased its saturation solubility and dissolution rate 
to a great extent but also change the pharmacokinetic profile of OA after oral administration. 
Oral bioavailability of OA was enhanced by the NS formulation, which showed much higher 
Cmax and rF % than the coarse suspension group. Dose-independent pharmacokinetics of OA 
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CHAPTER 4. GENERAL CONCLUSIONS  
NS provides the opportunity of improving saturation solubility, dissolution rate, 
bioefficacy and pharmacokinetic attribute for low aqueous solubility compounds with 
therapeutic efficacy, especially many potential compounds from natural sources. Although 
there are compounds with many promising properties such as low toxic and ready 
biodegradability (104-106), the bioavailability of the compounds would eventually determine 
their usefulness as a therapeutic agent. Thus, for a poorly water soluble drug, the ability of 
the drug to dissolve upon ingestion and present a reasonable bioavailability so as to give the 
required therapeutic blood level is of paramount importance. Amongst the methods of 
enhancing drug solubility, the method of producing nanosized and physiologically acceptable 
dispersions by only the application of gentle heat and moderate shear stress (109) is highly 
desirable. Thus, this study was directed at the search of desirable methods to produce 
nanoparticles. As nanoparticles required a stabilizing agent, a popular class of surfactant used 
in the preparation of beverages was explored. Highly purified SE was selected as it is 
generally regarded as non-toxic and posses a good taste.  SEs were not well studied as 
stabilizers in preparing nanoscaled products. This present study was the first to employ SEs 
as main stabilizer for the preparation of NS.  
Two approaches for the preparation of nanoparticles were evaluated, namely the 
emulsion-solvent evaporation method (ESE) and wet ball milling (WBM) method. Both of 
the methods applied to prepare SEOA NS yielded nanosized –range of particles (below 100 
nm). NS produced were found to be spherical in shape and covered by distinct SE coating on 
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the periphery, as examined by the TEM. Saturation solubility of NS prepared via bottom-up 
and top-down methods were both much higher than the free drug. The saturation solubility of 
manufactured NS ranged from 0.66 mg/mL (SEOA91101 NS) to 1.89 mg/mL (SEOA4121 
NS), and 2.08 mg/mL (SEOA-EAC NS) to 5.49 mg/mL (SEOA-HBD NS) respectively. As a 
consequence, the in vitro dissolution rate and cytotoxicity of SEOA NS prepared via the two 
methods were also much higher than free drug. The oral bioavailability produced a big 
increase, a 6-7 folds increase (SEOA4121 NS) to 12 folds increase (SEOA-GBD NS). 
However, as there were differences in the preparation routes, the two methods also 
produced NS particles with some contrasts in their characteristics (Table 4.1). 
Firstly, the average particle size and PDI of the two production methods’ products were 
similar and statistically insignificant (p>0.05). However, the average particle size for WBM’s 
products ranged much wider (with bigger variation) than ESE’s products. The median size of 
WBM (77.09 nm and 0.35 PDI) NS was much smaller than ESE’s group (101.6 nm and 0.57 
PDI). This had implied that the WBM method produced much widely distributed NS since 
the production parameters for WBM method also ranged much wider than the ESE method. 
Secondly, WBM produced NS had much higher saturation solubility (3.79 mg/mL to 
0.88 mg/mL) and less EE % (37.87 % to 55.77 %) than ESE. Top-down method utilized 
more energy resulting in more heat generated. Therefore, the higher energy method enabled 
much more hydrophobic OA to be entrapped, coated and presented as NS. However, the 
lower EE % indicated that the increase of solubility had its maximum limit. In addition, with 
the restriction of SE stabilization ability and Ostwald ripening effect, too high a saturation 
solubility led to instability and product failure. 
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Thirdly, when comparing the stability index, ESE method was superior in both chemical 
and physical stability (p<0.05). The higher input of energy and heat generation caused some 
level of instability. 
  However, it was well accepted that Ostwald ripening had some major impact on 






[C( ) V D / RT]
dt 9
     , Ostwald ripening rate ω (indicating as change 
rate of particle size) correlated with the saturation solubility C(∞) and interfacial tension γ.  
 
 
Table 4.1 character comparison between bottom-up and top-down methods 
 
 
emulsion-solvent-evaporation wet ball milling 
Particle size (nm) 112.85 ± 27.15 93.67 ± 52.31 
PDI 0.54 ± 0.09 0.53 ± 0.29 
Saturation solubility (mg/mL) 0.88 ± 0.42 ** 3.79 ± 1.24 
EE % 55.77 ± 22.33 * 37.87 ± 12.36 
15-day size change (%) 37.68 ± 22.62 * 765.15 ± 1033.94 
30-day size change (%) 185.57 ± 132.60 * 1173.22 ± 1525.96 
30-day relative con. (%) 87.06 ± 5.43 * 81.32 ± 6.59 
 
Data represent 3 independent experiments repeated in triplicate. Values are presented as 
means ± std. *, p<0.05, **, P<0.01. Statistics were carried out by independent- samples T 
test. 
 
Since the saturation solubility of WBM increased much higher than ESE, as according 
to LSW theory, the Ostwald ripening rates were much faster in the WBM than the ESE 
method. Although more surfactant reduced the interfacial tension and slowed down the rate 
of change, the increase in saturation solubility appeared to override the slowing down effect. 
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Last but not least, to add further discussion to the stability issue, it was valuable to 
compare the most stable NS prepared by the two methods. As discussed earlier, the SEL : 
SEP ratio and SE : OA ratio played important roles in determining the NS characteristics 
prepared by both of the two methods. The most stable formulation in ESE method was SEOA 
91101 NS (SEL : SEP at 9 : 1, w/w; SE : OA at 10 : 1, w/w) and in WBM method was 
SEOA-GBD NS (600 rpm, 3 h, SEL : SEP at 9 : 1, w/w; SE : OA at 1 : 1, w/w). Although 
both the NS products were similar in SEL : SEP ratio, they were rather different in their SE : 
OA ratio.  
When using ESE, the amount of SE needed was constant and that of OA varied. SE : 
OA at 10 : 1 (w/w) had the least amount of OA and the saturation solubility of produced NS 
was the smallest. With similar lowing of the interfacial tension effect (same amount of SE) 
and lowest saturation solubility, SEOA 91101 NS received the lowest Ostwald ripening rate 
and hence most stable. Although SELOA and SEPOA also had the 10 : 1 ratio of SE : OA, 
the SEL : SEP at 9 : 1 (w/w) also aided in maintaining stable NS structure, they were not as 
stable as SEOA 91101 NS. 
On the contrary, WBM varied in the amount of SE and OA was kept constant. Although 
the increase in SE could contributed to a reduction in the interfacial tension and slow down 
the Ostwald ripening process, the effects of increased saturation solubility which also arose 
from larger SE : OA ratio (10 : 1) could override the slowing down effect resulted in 
worsening the physical stability. This deduction may explain the anomaly why in WBM 
method, the SE : OA at 1 : 1 was more stable than 10 : 1. Similarly, SEL : SEP at 9 : 1 (w/w) 
was shown to be the better stabilizing factor. 
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As a suspension form, SEOA NS was only stable for a limited time span. The future 
work should focus on formulating more stable products that could be optimized as SEOA NS 
suitable to be incorporated into tablets and posses the required shelf-life as required for 
general marketed product. DOE will be applied in optimizing the production settings with 
multiple responses and variables. Pharmacokinetics study (bioavailability and distribution 
among others), pharmacokinetic-pharmacodynamic interaction and toxicology studies will be 
carried out to compare SEOA NS in tablets with the marketed drug products by using both 
normal animals and disease model animals. In our study, although the solubility and 
bioefficacy of SEOA NS has been enhanced greatly comparing to free drug, the cytotoxicity 
to A549 cell line is still weak. We will try to evaluate the liverprotection effect by in vitro 
and in vivo. Further directions may also include the clinical trials to ascertain the findings in 
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